

## WEST Search History

DATE: Thursday, October 16, 2003

### Set Name Query

side by side

### Hit Count Set Name

result set

*DB=USPT,PGPB,EPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES;  
OP=ADJ*

L6	((plasminogen adj activator?) or (matrix adj metalloproteinase?)) same \$ricin?	4	L6
L5	cancer adj associated adj protease? and factor adj Xa	1	L5
L4	cancer adj associated adj protease? and Xa	1	L4
L3	cancer adj associated adj protease? same Xa	0	L3
L2	cancer adj associated adj protease?	15	L2
L1	6531125.pn.	1	L1

END OF SEARCH HISTORY

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 4 of 4 returned.****1. Document ID: US 20030130506 A1**

L6: Entry 1 of 4

File: PGPB

Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030130506

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030130506 A1

TITLE: Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation

PUBLICATION-DATE: July 10, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zook, Scott E.	Del Mar	CA	US	
Dagnino, Raymond JR.	San Diego	CA	US	
Deason, Michael E.	Poway	CA	US	
Bender, Steven L.	Oceanside	CA	US	
Melnick, Michael J.	San Diego	CA	US	

US-CL-CURRENT: 544/60; 546/14, 546/290

Full	Title	Creation	Front	Keywords	Classification	Date	Reference	Sequence	Attachment	Claims	Page	Drawings	Image
------	-------	----------	-------	----------	----------------	------	-----------	----------	------------	--------	------	----------	-------

**2. Document ID: US 6500948 B1**

L6: Entry 2 of 4

File: USPT

Dec 31, 2002

US-PAT-NO: 6500948

DOCUMENT-IDENTIFIER: US 6500948 B1

TITLE: Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof

DATE-ISSUED: December 31, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zook; Scott E.	Del Mar	CA		
Dagnino, Jr.; Raymond	San Diego	CA		
Deason; Michael E.	Poway	CA		
Bender; Steven L.	Oceanside	CA		
Melnick; Michael J.	San Diego	CA		

US-CL-CURRENT: 544/60; 544/58.4, 544/58.6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequence	Attachment	Claims	Full	Draw Data	Image
------	-------	----------	-------	--------	----------------	------	-----------	----------	------------	--------	------	-----------	-------

## 3. Document ID: US 6153757 A

L6: Entry 3 of 4

File: USPT

Nov 28, 2000

US-PAT-NO: 6153757

DOCUMENT-IDENTIFIER: US 6153757 A

TITLE: Metalloproteinase inhibitors and intermediates useful for their preparation

DATE-ISSUED: November 28, 2000

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Zook; Scott E.	Del Mar	CA		
Dagnino, Jr.; Raymond	San Diego	CA		
Deason; Michael E.	Poway	CA		
Bender; Steven L.	Oceanside	CA		
Melnick; Michael J.	San Diego	CA		

US-CL-CURRENT: 546/301; 546/302, 546/339, 548/342.5, 548/377.1, 549/497, 549/78,  
562/833

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequence	Attachment
------	-------	----------	-------	--------	----------------	------	-----------	----------	------------

Full	Draw Data	Image
------	-----------	-------

## 4. Document ID: US 5753653 A

L6: Entry 4 of 4

File: USPT

May 19, 1998

US-PAT-NO: 5753653

DOCUMENT-IDENTIFIER: US 5753653 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

DATE-ISSUED: May 19, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bender; Steven L.	Oceanside	CA		
Melnick; Michael J.	San Diego	CA		

US-CL-CURRENT: 514/227.5; 514/227.8, 514/235.5, 514/237.5, 514/255.01, 514/256,  
514/269, 544/111, 544/131, 544/158, 544/161, 544/319, 544/335, 544/360, 544/383,  
544/58.2, 544/58.4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequence	Attachment
------	-------	----------	-------	--------	----------------	------	-----------	----------	------------

Full	Draw Data	Image
------	-----------	-------

Generate Collection

Print

Term	Documents
PLASMINOGEN	13522
PLASMINOGENS	75
MATRIX	456934
MATRICES	60071
MATRIXES	6605
ACTIVATOR?	0
ACTIVATORE	1
ACTIVATORG	1
ACTIVATORI	1
ACTIVATORM	1
ACTIVATORS	32121
(((PLASMINOGEN ADJ ACTIVATOR?) OR (MATRIX ADJ METALLOPROTEINASE?)) SAME \$RICIN?).USPT,PGPB,EPAB,DWPI,TDBD.	4

[There are more results than shown above. Click here to view the entire set.](#)

**Display Format:** -

[Change Format](#)

[Previous Page](#)

[Next Page](#)

**WEST**[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 1 of 1 returned.**

1. Document ID: US 6593132 B1

L4: Entry 1 of 1

File: USPT

Jul 15, 2003

US-PAT-NO: 6593132

DOCUMENT-IDENTIFIER: US 6593132 B1

TITLE: Ricin-like toxin variants for treatment of cancer, viral or parasitic infections

DATE-ISSUED: July 15, 2003

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Borgford; Thor	Burnaby			CA

US-CL-CURRENT: [435/320.1](#); [530/350](#), [530/370](#), [536/23.1](#), [536/23.4](#)

<a href="#">Full</a>	<a href="#">Title</a>	<a href="#">CLS.1</a>	<a href="#">REF.1</a>	<a href="#">SEQ.1</a>	<a href="#">ATT.1</a>
----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

[Generate Collection](#)[Print](#)

Term	Documents
CANCER	129183
CANCERS	33933
ASSOCIATED	1704136
ASSOCIATEDS	6
XA	17865
XAS	1277
PROTEASE?	0
PROTEASEA	1
PROTEASEB	5
PROTEASEC	4
PROTEASED	7
(CANCER ADJ ASSOCIATED ADJ PROTEASE? AND XA).USPT,PGPB,EPAB,DWPI,TDBD.	1

[There are more results than shown above. Click here to view the entire set.](#)**Display Format:** -[Change Format](#)

FILE 'HOME' ENTERED AT 19:02:04 ON 16 OCT 2003

=> file bioscience medicine

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'ADISCTI' ENTERED AT 19:02:18 ON 16 OCT 2003

COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 19:02:18 ON 16 OCT 2003

COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 19:02:18 ON 16 OCT 2003

COPYRIGHT (C) 2003 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 19:02:18 ON 16 OCT 2003

FILE 'ANABSTR' ENTERED AT 19:02:18 ON 16 OCT 2003

COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 19:02:18 ON 16 OCT 2003

COPYRIGHT 2003 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 19:02:18 ON 16 OCT 2003

COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 19:02:18 ON 16 OCT 2003

COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOSIS' ENTERED AT 19:02:18 ON 16 OCT 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 19:02:18 ON 16 OCT 2003

COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 19:02:18 ON 16 OCT 2003

COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 19:02:18 ON 16 OCT 2003

COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 19:02:18 ON 16 OCT 2003

FILE 'CAPLUS' ENTERED AT 19:02:18 ON 16 OCT 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 19:02:18 ON 16 OCT 2003

COPYRIGHT (c) 2003 DECHEMA eV

FILE 'CEN' ENTERED AT 19:02:18 ON 16 OCT 2003

COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 19:02:18 ON 16 OCT 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 19:02:18 ON 16 OCT 2003

COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGLAUNCH' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGMONOG2' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGNL' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DRUGUPDATES' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 19:02:18 ON 16 OCT 2003

FILE 'FOMAD' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 International Food Information Service

FILE 'GENBANK' ENTERED AT 19:02:18 ON 16 OCT 2003

FILE 'HEALSAFE' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'JICST-EPLUS' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)

FILE 'KOSMET' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 19:02:18 ON 16 OCT 2003

FILE 'NIOSHTIC' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 19:02:18 ON 16 OCT 2003  
Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.  
All rights reserved. (2003)

FILE 'NUTRACEUT' ENTERED AT 19:02:18 ON 16 OCT 2003  
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 19:02:18 ON 16 OCT 2003  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 WIPO

FILE 'PHAR' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 19:02:18 ON 16 OCT 2003  
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT 2003 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Prous Science

FILE 'TOXCENTER' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 ACS



FILE 'USPATFULL' ENTERED AT 19:02:18 ON 16 OCT 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 19:02:18 ON 16 OCT 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'VETU' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'IPA' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 American Society of Hospital Pharmacists (ASHP)

FILE 'NAPRALERT' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Board of Trustees of the University of Illinois,  
University of Illinois at Chicago.

FILE 'NLDB' ENTERED AT 19:02:18 ON 16 OCT 2003  
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

=> s ricin? (s) ( protease? or (matrix (w) proteinase?)) and pharmaceutical (w)  
composition and treat?

L1	0	FILE ADISCTI
L2	0	FILE ADISINSIGHT
L3	0	FILE ADISNEWS
L4	0	FILE AGRICOLA
L5	0	FILE ANABSTR
L6	0	FILE AQUASCI
L7	0	FILE BIOBUSINESS
L8	0	FILE BIOCOMMERCE
L9	3	FILE BIOSIS
L10	0	FILE BIOTECHDS
L11	0	FILE BIOTECHNO
L12	0	FILE CABA
L13	0	FILE CANCERLIT
L14	1	FILE CAPLUS
L15	0	FILE CEABA-VTB
L16	0	FILE CEN
L17	0	FILE CIN
L18	0	FILE CONFSCI
L19	0	FILE CROPB
L20	0	FILE CROPU
L21	0	FILE DGENE
L22	0	FILE DRUGB
L23	0	FILE DRUGLAUNCH
L24	0	FILE DRUGMONOG2
L25	0	FILE DRUGNL
L26	0	FILE DRUGU
L27	0	FILE DRUGUPDATES
L28	0	FILE EMBAL
L29	0	FILE EMBASE
L30	0	FILE ESBIODBASE

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH  
FIELD CODE - 'AND' OPERATOR ASSUMED 'RICIN? (S) '

L31	0	FILE FEDRIP
L32	0	FILE FOMAD
L33	0	FILE FOREGE

```

L34      0 FILE FROSTI
L35      0 FILE FSTA
L36      0 FILE GENBANK
L37      0 FILE HEALSAFE
L38      4 FILE IFIPAT
L39      0 FILE JICST-EPLUS
L40      0 FILE KOSMET
L41      1 FILE LIFESCI
L42      0 FILE MEDICONF
L43      0 FILE MEDLINE
L44      0 FILE NIOSHTIC
L45      0 FILE NTIS
L46      0 FILE NUTRACEUT
L47      0 FILE OCEAN
L48      0 FILE PASCAL
L49      0 FILE PCTGEN
L50      0 FILE PHAR
L51      0 FILE PHARMAML
L52      0 FILE PHIC
L53      0 FILE PHIN
L54      0 FILE PROMT
L55      0 FILE RDISCLOSURE
L56      0 FILE SCISEARCH
L57      0 FILE SYNTHLINE
L58      0 FILE TOXCENTER
L59      83 FILE USPATFULL
L60      2 FILE USPAT2
L61      0 FILE VETB
L62      0 FILE VETU
L63      4 FILE WPIDS
L64      0 FILE IPA
L65      0 FILE NAPRALERT
L66      0 FILE NLDB

```

TOTAL FOR ALL FILES

```

L67      98 RICIN? (S) (PROTEASE? OR (MATRIX (W) PROTEINASE?)) AND PHARMACEU
          TICAL (W) COMPOSITION AND TREAT?

```

=> dup rem 167

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGLAUNCH, DRUGMONOG2, DRUGUPDATES, FEDRIP, FOREGE, GENBANK, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, RDISCLOSURE, SYNTHLINE'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L67

```

L68      89 DUP REM L67 (9 DUPLICATES REMOVED)

```

=> d ibib abs 168 1-89

```

L68  ANSWER 1 OF 89  BIOSIS  COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
      DUPLICATE 1

```

ACCESSION NUMBER: 2003:366623 BIOSIS

DOCUMENT NUMBER: PREV200300366623

TITLE: Ricin-like toxin variants for **treatment** of cancer, viral or parasitic infections.

AUTHOR(S): Borgford, Thor (1)

CORPORATE SOURCE: (1) Burnaby, Canada Canada

ASSIGNEE: Twinstrand Therapeutics Inc., Vancouver, Canada

PATENT INFORMATION: US 6593132 July 15, 2003

SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (July 15 2003) Vol. 1272, No. 3, pp. No Pagination. <http://www.uspto.gov/web/menu/patdata.html>. e-file.

ISSN: 0098-1133.

DOCUMENT TYPE: Patent

LANGUAGE: English

AB The present invention provides a protein having an A chain of a **ricin**-like toxin, a B chain of a **ricin**-like toxin and a heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a disease specific **protease** such as a cancer, fungal, viral or parasitic **protease**. The invention also relates to a nucleic acid molecule encoding the protein and to expression vectors incorporating the nucleic acid molecule. Also provided is a method of inhibiting or destroying mammalian cancer cells, cells infected with a virus, a fungus, or parasite, or parasites utilizing the nucleic acid molecules and proteins of the invention and **pharmaceutical compositions** for **treating** human cancer, viral infection, fungal infection, or parasitic infection.

L68 ANSWER 2 OF 89 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
DUPLICATE 2

ACCESSION NUMBER: 2003:183592 BIOSIS  
DOCUMENT NUMBER: PREV200300183592  
TITLE: Antiviral ricin-like proteins.  
AUTHOR(S): Borgford, Thor (1)  
CORPORATE SOURCE: (1) Burnaby, Canada Canada  
ASSIGNEE: Twinstrand Therapeutics Inc., Vancouver, Canada  
PATENT INFORMATION: US 6531125 March 11, 2003  
SOURCE: Official Gazette of the United States Patent and Trademark  
Office Patents, (Mar. 11 2003) Vol. 1268, No. 2, pp. No  
Pagination. <http://www.uspto.gov/web/menu/patdata.html>.  
e-file.  
ISSN: 0098-1133.  
DOCUMENT TYPE: Patent  
LANGUAGE: English

AB The present invention provides a protein having an A chain of a **ricin**-like toxin, a B chain of a **ricin**-like toxin and a heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a retroviral **protease** such as HIV or an HTLV **protease**. The invention also relates to a nucleic acid molecule encoding the protein and to expression vectors incorporating the nucleic acid molecule. Also provided is a method of inhibiting or destroying mammalian cells infected with a retrovirus utilizing the proteins of the invention; and **pharmaceutical compositions** for **treating** HIV infections and human T-cell leukemias involving HTLV.

L68 ANSWER 3 OF 89 USPATFULL on STN DUPLICATE 3

ACCESSION NUMBER: 2003:140556 USPATFULL  
TITLE: Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis  
INVENTOR(S): Schlesinger, Sondra, St.Louis, MO, UNITED STATES  
Frolov, Ilya, St.Louis, MO, UNITED STATES  
Dubenssky, Thomas W., JR., Delmar, CA, UNITED STATES  
Polo, John M., Encinitas, CA, UNITED STATES  
Belli, Barbara A., San Diego, CA, UNITED STATES  
Dryga, Sergev A., Fort Collins, CO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003096397	A1	20030522
	US 6592874	B2	20030715
APPLICATION INFO.:	US 2000-507362	A1	20000218 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-944465, filed on 6 Oct 1997, PENDING Continuation-in-part of Ser. No. US 1997-833148, filed on 4 Apr 1997, ABANDONED Continuation-in-part of Ser. No. US 1996-679640, filed on 12 Jul 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-668953, filed on 24 Jun 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-628594, filed		

on 5 Apr 1996, ABANDONED

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097  
 NUMBER OF CLAIMS: 33  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 63 Drawing Page(s)  
 LINE COUNT: 8169

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 4 OF 89 IFIPAT COPYRIGHT 2003 IFI on STN  
 AN 10305833 IFIPAT;IFIUDB;IFICDB  
 TITLE: CYTOKINE ACTIVITY REGULATOR MOLECULES FROM TICK SALIVARY GLANDS  
 INVENTOR(S): Fuchsberger; Norbert, Bratislava, SK  
 Gasperik; Juraj, Bratislava, SK  
 Hajnicka; Valeria, Bratislava, SK  
 Kocakova; Paula, Bratislava, SK  
 Slovak; Mirko, Bratislava, SK  
 PATENT ASSIGNEE(S): Unassigned  
 AGENT: David A. Jackson KLAUBER & JACKSON, 4th Floor, 411 Hackensack Street, Hackensack, NJ, 07601, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2003050244	A1	20030313
APPLICATION INFORMATION:	US 2002-217342		20020812

	NUMBER	DATE
PRIORITY APPLN. INFO.:	GB 2000-32458	20000211
	GB 2000-317081	20001222
FAMILY INFORMATION:	US 2003050244	20030313
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Patent Application - First Publication	
	CHEMICAL	
	APPLICATION	
NUMBER OF CLAIMS:	59 20 Figure(s).	
	DESCRIPTION OF FIGURES:	

FIG. 1 shows the fractionation of salivary gland extract (SGE) of Dermacentor reticulatus adult female ticks fed for 5 days using fast phase liquid chromatography (FPLC). Arrows indicate the positions of molecular weight markers (Boehringer).

FIG. 2 shows the effect of tick SGE on IL-8 production by the human monocytic leukemic cell line, THP-1, measured by enzyme linked immunoabsorbent assay (ELISA). LPS=lipopolysaccharide; SGE from D. reticulatus adult females fed for 5 days.

FIG. 3 shows the detection by ELISA of 100 pg of IL-8 after 2 hours incubation with SGE from different tick species. D.R. 3D F=Dermacentor reticulatus adult females fed for 3 days; D.R. 5D F=D. reticulatus adult females fed for 5 days; D.R. 3D M=D. reticulatus adult males fed for 3 days; D.R. 5D M=D. reticulatus adult males fed for 5 days; R.A. 5D F=Rhipicephalus appendiculatus adult

females fed for 5 days; R.A. 5D M=R. appendiculatus adult males fed for 5 days; A.V. 15D M=Amblyomma variegatum adult males fed for 15 days; I.R. 5D F=Ixodes \*\*\*ricinus\*\*\* adult females fed for 5 days; H.I. 5D F=Haemaphysalis inermis adult females fed for 5 days; IL-8=IL-8 alone not **treated** with SGE.

FIG. 4 shows the anti-chemokine activity of FPLC fractions (1  $\mu$ l) of SGE derived from 5 days fed Dermacentor reticulatus female ticks (174 ticks; 4.12 mg proteins) detected by ELISA.

FIG. 5 shows the anti-chemokine activity of FPLC fractions (400  $\mu$ l) of SGE derived from 5 to 6 days fed Dermacentor reticulatus male ticks (522 ticks; 3.3 mg proteins) detected by ELISA.

FIG. 6 shows the anti-chemokine activity of FPLC fractions (400  $\mu$ l) of SGE derived from 5 to 6 days fed Rhipicephalus appendiculatus female ticks (121 ticks; 1.966 mg proteins) detected by ELISA.

FIG. 7 shows the anti-chemokine activity of FPLC fractions (400  $\mu$ l) of SGE derived from 11 to 12 days fed Amblyomma variegatum male ticks (65 ticks; 2.39 mg proteins) detected by ELISA.

FIG. 8 shows the anti-chemokine activity of saliva from female: Rhipicephalus appendiculatus 10 ticks (15.0  $\mu$ g protein) fed for 6 days (R.A.6D F), Dermacentor reticulatus 19 ticks (8.5  $\mu$ g protein) fed for 5 days (D.R.5D F), Amblyomma variegatum 6 ticks (10.2  $\mu$ g protein) fed for 10 days (A.V.10D F). ELISA results are shown as % optical density in the presence of saliva compared with the control (chemokine not **treated** with saliva).

FIG. 9 shows the anti-eotaxin activity of FPLC fractions of SGE derived from (A) Amblyomma variegatum male ticks (0.5  $\mu$ l fractions) and (B) Dermacentor reticulatus male ticks (1  $\mu$ l fractions) using 80 pg per **treatment** of eotaxin, detected by ELISA.

FIG. 10 shows the anti-IP-10 activity of FPLC fractions (1  $\mu$ l) of SGE derived from 5 to 6 days fed Dermacentor male ticks using 60 pg IP-10 per \*\*\*treatment\*\*\* detected by ELISA.

FIG. 11 shows the effect of trypsin **treatment** of SGE derived from 5 days fed Dermacentor reticulatus female ticks: (A) on the total protein profile (broken line untreated, continuous line after trypsin **treatment**), and (B-E) on the anti-chemokine activity of FPLC fractions from the SGE either \*\*\*treated\*\*\* with trypsin (

FIG. 12 shows the detection by ELISA of IL-8 after incubation with D. reticulatus SGE pretreated with a **protease** inhibitor cocktail. P. inhib.=**protease** inhibitor; PBS=phosphate buffered saline (control).

FIG. 13 shows the detection by ELISA of 100 pg of IL-8 after incubation with FPLC fractions of SGE derived from D. reticulatus adult females that were either untreated (SGE) or **treated** with the metalloproteinase inhibitor, ethylene diamine tetraacetic acid (SGE+EDTA).

FIG. 14 shows the binding of <sup>125</sup>I-IL-8 to: (a) SGE of D. reticulatus adult females fed for 5 days (A) and anti-IL-8 antibody (B) as a positive control; (b) selected FPLC fractions of different ticks species (shown in left hand panels) as indicated (shown in right hand panels)-Dr16, Dr21, Dr32, Dr39, Dr50, Dr26, Dr35, Dr40, are the indicated fractions from D. reticulatus female ticks fed for 5 days and Ra39, Ra32, are the indicated fractions from R. appendiculatus female ticks fed for 5 days, aIL-8 is goat anti-IL-8 antibody (positive control).

FIG. 15 shows cross-linking of <sup>125</sup>I-IL-8 to selected FPLC fractions of SGE derived from D. reticulatus adult females fed for 5 days. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) run under either reducing (A) conditions with beta-mercaptoethanol, or non-reducing (B) conditions i.e. without beta-mercaptoethanol. Samples in lanes 1 to 3 were not cross-linked whereas samples in lanes 4 to 6 were cross-linked with DTSSP. Lane 1=<sup>125</sup>I-IL-8; lane 2=<sup>125</sup>I-IL8+fraction 35; lane 3=<sup>125</sup>I-IL-8+fraction 41; lane 4=<sup>125</sup>I-IL-8; lane 5=<sup>125</sup>I-IL-8+fraction 35; lane 6=<sup>125</sup>I-IL-8+fraction 41; M.W.=molecular weight markers.

FIG. 16 shows SDS-PAGE of FPLC fraction 40 of SGE derived from D. reticulatus adult females run under non-reducing conditions. M. W.=molecular weight markers and track (A) are silver stained SDS-polyacrylamide gels and (B) shows <sup>125</sup>I-IL-8 binding following electroblotting onto a PVDF membrane.

FIG. 17 shows the inhibition by tick SGE of <sup>125</sup>I-IL-8 binding to its cell receptor. IL-8\*=<sup>125</sup>I-IL-8 binding to its receptor; IL8+<sup>125</sup>I-IL-8=radiolabelled IL-8 bound to its receptor in the presence of cold (unlabelled) IL-8; SGE (10

mu g)+125I-IL8=radiolabelled IL-8 bound to its receptor when **treated** with 10 mu g of tick SGE; SGE (50 mu g)+125I-IL-8=radiolabelled IL-8 bound to its receptor when **treated** with 50 mu g of tick SGE. SGE was from *D. reticulatus* adult females fed for 5 days. FIG. 18 shows the inhibition of 125I-IL-8 binding to its cell receptor by FPLC fractions of tick SGE. IL-8\*=125I-IL-8 binding to its receptor; IL-8+125I-IL-8=radiolabelled IL-8 bound to its receptor in the presence of cold (unlabelled) IL-8; fr. xx=radiolabelled IL-8 bound to its receptor when **\*\*\*treated\*\*\*** with fraction as numbered. SGE is from *D. reticulatus* adult females fed for 5 days.

FIG. 19 shows inhibition by tick SGE of the chemotactic activity of IL-8. NC=untreated cells (negative control); fMLP 106=formylmethionyl-leucylphenylalanine at 10<sup>-6</sup> M (positive control of chemotaxis); IL-8 50,000 U=demonstration of chemotactic activity of IL-8; IL-8+anti-IL-8=inhibition of chemotactic activity of IL-8 with specific antibodies; IL-8+SGD D.R.=IL-8 **\*\*\*treated\*\*\*** with *D. reticulatus* SGE; IL-8+fr. 35=IL-8 **treated** with FPLC fraction 35 of *D. reticulatus* SGE; IL-8+fr. 39=IL-8 **treated** with FPLC fraction 39 of *D. reticulatus* SGE; IL-8+fr. 50-52=IL-8 **treated** with FPLC fractions 50 to 52 of *D. reticulatus* SGE.

FIG. 20 shows the results of 2D gel electrophoresis of: A SGE prepared from *D. reticulatus* females ticks fed for 5 days, (B) FPLC fractions 37+38 of *D. reticulatus* females ticks fed for 5 days, (C) FPLC fractions 42+43 of *D. reticulatus* females ticks fed for 5 days, (D) FPLC fraction 41 of *D. reticulatus* females ticks fed for 5 days (stained with Coomassie blue), (E) saliva prepared from *A. variegatum* female ticks fed for 10 days, and (F) SGE of from *A. variegatum* female ticks fed for 10 days.

AB The present invention relates to cytokine activity regulator molecules (CARMs) and their use in controlling the action of cytokines, particularly chemokines. In particular, the invention relates to CARMs that are derived from parasite salivary glands. The invention also relates to the use of CARMs in the **treatment** of diseases and allergies and in the production of vaccines that protect mammals, including humans, against the transmission of pathogenic (disease-causing) microorganisms by certain parasites.

CLMN 59 20 Figure(s).

FIG. 1 shows the fractionation of salivary gland extract (SGE) of *Dermacentor reticulatus* adult female ticks fed for 5 days using fast phase liquid chromatography (FPLC). Arrows indicate the positions of molecular weight markers (Boehringer).

FIG. 2 shows the effect of tick SGE on IL-8 production by the human monocytic leukemic cell line, THP-1, measured by enzyme linked immunoabsorbent assay (ELISA). LPS=lipopolysaccharide; SGE from *D. reticulatus* adult females fed for 5 days.

FIG. 3 shows the detection by ELISA of 100 pg of IL-8 after 2 hours incubation with SGE from different tick species. D.R. 3D F=*Dermacentor reticulatus* adult females fed for 3 days; D.R. 5D F=*D. reticulatus* adult females fed for 5 days; D.R. 3D M=*D. reticulatus* adult males fed for 3 days; D.R. 5D M=*D. reticulatus* adult males fed for 5 days; R.A. 5D F=*Rhipicephalus appendiculatus* adult females fed for 5 days; R.A. 5D M=*R. appendiculatus* adult males fed for 5 days; A.V. 15D M=*Amblyomma variegatum* adult males fed for 15 days; I.R. 5D F=*Ixodes ricinus* adult females fed for 5 days; H.I. 5D F=*Haemaphysalis inermis* adult females fed for 5 days; IL-8=IL-8 alone not **treated** with SGE.

FIG. 4 shows the anti-chemokine activity of FPLC fractions (1 mu l) of SGE derived from 5 days fed *Dermacentor reticulatus* female ticks (174 ticks; 4.12 mg proteins) detected by ELISA.

FIG. 5 shows the anti-chemokine activity of FPLC fractions (400 mu l) of SGE derived from 5 to 6 days fed *Dermacentor reticulatus* male ticks (522 ticks; 3.3 mg proteins) detected by ELISA.

FIG. 6 shows the anti-chemokine activity of FPLC fractions (400 mu l) of SGE derived from 5 to 6 days fed *Rhipicephalus appendiculatus* female ticks (121 ticks; 1.966 mg proteins) detected by ELISA.

FIG. 7 shows the anti-chemokine activity of FPLC fractions (400 mu l) of SGE derived from 11 to 12 days fed *Amblyomma variegatum* male ticks (65 ticks; 2.39 mg proteins) detected by ELISA.

FIG. 8 shows the anti-chemokine activity of saliva from female: *Rhipicephalus appendiculatus* 10 ticks (15.0  $\mu$ g protein) fed for 6 days (R.A.6D F), *Dermacentor reticulatus* 19 ticks (8.5  $\mu$ g protein) fed for 5 days (D.R.5D F), *Amblyomma variegatum* 6 ticks (10.2  $\mu$ g protein) fed for 10 days (A.V.10D F). ELISA results are shown as % optical density in the presence of saliva compared with the control (chemokine not **treated** with saliva).

FIG. 9 shows the anti-eotaxin activity of FPLC fractions of SGE derived from (A) *Amblyomma variegatum* male ticks (0.5  $\mu$ l fractions) and (B) *Dermacentor reticulatus* male ticks (1  $\mu$ l fractions) using 80 pg per **treatment** of eotaxin, detected by ELISA.

FIG. 10 shows the anti-IP-10 activity of FPLC fractions (1  $\mu$ l) of SGE derived from 5 to 6 days fed *Dermacentor* male ticks using 60 pg IP-10 per **treatment** detected by ELISA.

FIG. 11 shows the effect of trypsin **treatment** of SGE derived from 5 days fed *Dermacentor reticulatus* female ticks: (A) on the total protein profile (broken line untreated, continuous line after trypsin **treatment**), and (B-E) on the anti-chemokine activity of FPLC fractions from the SGE either **treated** with trypsin (

FIG. 12 shows the detection by ELISA of IL-8 after incubation with *D. reticulatus* SGE pretreated with a **protease** inhibitor cocktail. P. inhib.=**protease** inhibitor; PBS=phosphate buffered saline (control).

FIG. 13 shows the detection by ELISA of 100 pg of IL-8 after incubation with FPLC fractions of SGE derived from *D. reticulatus* adult females that were either untreated (SGE) or **treated** with the metalloproteinase inhibitor, ethylene diamine tetraacetic acid (SGE+EDTA).

FIG. 14 shows the binding of 125I-IL-8 to: (a) SGE of *D. reticulatus* adult females fed for 5 days (A) and anti-IL-8 antibody (B) as a positive control; (b) selected FPLC fractions of different ticks species (shown in left hand panels) as indicated (shown in right hand panels)-Dr16, Dr21, Dr32, Dr39, Dr50, Dr26, Dr35, Dr40, are the indicated fractions from *D. reticulatus* female ticks fed for 5 days and Ra39, Ra32, are the indicated fractions from *R. appendiculatus* female ticks fed for 5 days, aIL-8 is goat anti-IL-8 antibody (positive control).

FIG. 15 shows cross-linking of 125I-IL-8 to selected FPLC fractions of SGE derived from *D. reticulatus* adult females fed for 5 days. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) run under either reducing (A) conditions with beta-mercaptoethanol, or non-reducing (B) conditions i.e. without beta-mercaptoethanol. Samples in lanes 1 to 3 were not cross-linked whereas samples in lanes 4 to 6 were cross-linked with DTSSP. Lane 1=125I-IL-8; lane 2=125I-IL8+fraction 35; lane 3=125I-IL-8+fraction 41; lane 4=125I-IL-8; lane 5=125I-IL-8+fraction 35; lane 6=125I-IL-8+fraction 41; M.W. =molecular weight markers.

FIG. 16 shows SDS-PAGE of FPLC fraction 40 of SGE derived from *D. reticulatus* adult females run under non-reducing conditions. M. W.=molecular weight markers and track (A) are silver stained SDS-polyacrylamide gels and (B) shows 125I-IL-8 binding following electroblotting onto a PVDF membrane.

FIG. 17 shows the inhibition by tick SGE of 125I-IL-8 binding to its cell receptor. IL-8\*=125I-IL-8 binding to its receptor; IL8+125I-IL-8=radiolabelled IL-8 bound to its receptor in the presence of cold (unlabelled) IL-8; SGE (10  $\mu$ g)+125I-IL8=radiolabelled IL-8 bound to its receptor when **treated** with 10  $\mu$ g of tick SGE; SGE (50  $\mu$ g)+125I-IL-8=radiolabelled IL-8 bound to its receptor when **treated** with 50  $\mu$ g of tick SGE. SGE was from *D. reticulatus* adult females fed for 5 days.

FIG. 18 shows the inhibition of 125I-IL-8 binding to its cell receptor by FPLC fractions of tick SGE. IL-8\*=125I-IL-8 binding to its receptor; IL-8+125I-IL-8=radiolabelled IL-8 bound to its receptor in the presence of cold (unlabelled) IL-8; fr. xx=radiolabelled IL-8 bound to its receptor when **treated** with fraction as numbered. SGE is from *D. reticulatus* adult females fed for 5 days.

FIG. 19 shows inhibition by tick SGE of the chemotactic activity of IL-8.

NC=untreated cells (negative control); fMLP 106=formylmethionyl-leucylphenylalanine at 10<sup>-6</sup> M (positive control of chemotaxis); IL-8 50,000 U=demonstration of chemotactic activity of IL-8; IL-8+anti-IL-8=inhibition of chemotactic activity of IL-8 with specific antibodies; IL-8+SGD D.R.=IL-8 **treated** with D. reticulatus SGE; IL-8+fr. 35=IL-8 **treated** with FPLC fraction 35 of D. reticulatus SGE; IL-8+fr. 39=IL-8 **treated** with FPLC fraction 39 of D. reticulatus SGE; IL8+fr. 50-52=IL-8 **treated** with FPLC fractions 50 to 52 of D. reticulatus SGE.

FIG. 20 shows the results of 2D gel electrophoresis of: A SGE prepared from D. reticulatus females ticks fed for 5 days, (B) FPLC fractions 37+38 of D. reticulatus females ticks fed for 5 days, (C) FPLC fractions 42+43 of D. reticulatus females ticks fed for 5 days, (D) FPLC fraction 41 of D. reticulatus females ticks fed for 5 days (stained with Coomassie blue), (E) saliva prepared from A. variegatum female ticks fed for 10 days, and (F) SGE of from A. variegatum female ticks fed for 10 days.

L68 ANSWER 5 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:271037 USPATFULL  
 TITLE: Genes expressed in prostate cancer  
 INVENTOR(S): Faris, Mary, Los Angeles, CA, UNITED STATES  
 Pearson, Cecelia I., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003190640	A1	20031009
APPLICATION INFO.:	US 2002-252157	A1	20020529 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-295048P	20010531 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	INCYTE GENOMICS, INC., 3160 Porter Drive, Palo Alto, CA, 94304	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5162	

AB The present invention relates to a combination comprising a plurality of cDNAs which are differentially expressed in prostate cancer and which may be used in their entirety or in part as to diagnose, to stage to **treat** or to monitor the progression or **treatment** of prostate cancer.

L68 ANSWER 6 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:257234 USPATFULL  
 TITLE: Prevention and **treatment** of HCV infection employing antibodies directed against conformational and linear epitopes  
 INVENTOR(S): Fount, Steven K. H., Stanford, CA, UNITED STATES  
 Keck, Zhen-Yong, Redwood City, CA, UNITED STATES  
 PATENT ASSIGNEE(S): Board of Trustees of Leland Stanford Junior University (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003180284	A1	20030925
APPLICATION INFO.:	US 2002-188608	A1	20020702 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-728720, filed on 1 Dec 2000, PENDING Continuation-in-part of Ser. No. US 1999-430489, filed on 29 Oct 1999, PENDING Continuation-in-part of Ser. No. US 1998-187057, filed on 5 Nov 1998, ABANDONED		
DOCUMENT TYPE:	Utility		



FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Choate, Hall & Stewart, Exchange Place, 53 State  
Street, Boston, MA, 02109

NUMBER OF CLAIMS: 84  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 50 Drawing Page(s)  
LINE COUNT: 4366

AB Conformational epitopes of the envelope proteins E1 and E2 of the Hepatitis C virus (HCV) have been identified and characterized using a panel of monoclonal antibodies derived from patients infected with HCV. These conserved conformational and linear epitopes of the HCV protein E1 or E2 have been determined to be important in the immune response of humans to HCV and may be particularly important in neutralizing the virus. Based on the identification of these conformational epitopes, vaccines containing peptides and mimotopes with these conformational epitopes intact may be prepared and administered to patients to prevent and/or **treat** HCV infection. The identification of four distinct groups of monoclonal antibodies with each directed to a particular epitope of E1 or E2 may be used to stratify patients based on their response to HCV and may be used to determine a proper **treatment** regimen.

L68 ANSWER 7 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:237907 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis  
of colon cancer  
INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Secrist, Heather, Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166064	A1	20030904
APPLICATION INFO.:	US 2002-99926	A1	20020314 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223283P	20000803 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH  
AVE, SUITE 6300, SEATTLE, WA, 98104-7092  
NUMBER OF CLAIMS: 17  
EXEMPLARY CLAIM: 1  
LINE COUNT: 8531

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or **treatment** of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 8 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:219263 USPATFULL

TITLE: Compositions comprising tissue specific adenoviral vectors

INVENTOR(S): Little, Andrew S., Balboa Island, CA, UNITED STATES  
Lamparski, Henry G., San Mateo, CA, UNITED STATES  
Henderson, Daniel R., Palo Alto, CA, UNITED STATES  
Schuur, Eric R., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003152553	A1	20030814
APPLICATION INFO.:	US 2002-139089	A1	20020502 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-509591, filed on 2 Jun 2000, PENDING Continuation-in-part of Ser. No. US 1998-151376, filed on 10 Sep 1998, PENDING Continuation-in-part of Ser. No. US 1996-669753, filed on 26 Jun 1996, GRANTED, Pat. No. US 5871726 Continuation-in-part of Ser. No. US 1995-495034, filed on 27 Jun 1995, GRANTED, Pat. No. US 5698443 Continuation-in-part of Ser. No. US 1998-33428, filed on 2 Mar 1998, GRANTED, Pat. No. US 6254862 Continuation-in-part of Ser. No. US 1998-33555, filed on 2 Mar 1998, ABANDONED Continuation-in-part of Ser. No. US 1998-33333, filed on 2 Mar 1998, GRANTED, Pat. No. US 6197293		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-39597P	19970303 (60)
	US 1997-39763P	19970303 (60)
	US 1997-39762P	19970303 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 47 Drawing Page(s)

LINE COUNT: 5058

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising host cell specific adenovirus vehicles are provided for transfecting target host cells. The compositions comprise replication competent adenovirus having an adenovirus gene essential for replication under transcriptional control of a cell type specific transcriptional response element (TRE) and polyethylene glycol (PEG) as a masking agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 9 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:213882 USPATFULL

TITLE: Cell-specific adenovirus vectors comprising an internal ribosome entry site

INVENTOR(S): Yu, De-Chao, Foster City, CA, UNITED STATES  
Li, Yuanhao, Palo Alto, CA, UNITED STATES  
Little, Andrew S., Santa Ana, CA, UNITED STATES  
Henderson, Daniel R., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003148520	A1	20030807
APPLICATION INFO.:	US 2001-814351	A1	20010321 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-192156P	20000324 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025	
NUMBER OF CLAIMS:	58	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	5280	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are replication-competent adenovirus vectors comprising co-transcribed first and second genes under transcriptional control of a heterologous, target cell-specific transcriptional regulatory element (TRE), wherein the second gene is under translational control of an internal ribosome entry site. Methods for the preparation and use of such vectors are also provided. The vectors provide target cell-specific virus replication in applications such as cancer therapy and gene therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 10 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:172711 USPATFULL

TITLE: Target cell-specific adenoviral vectors containing E3 and methods of use thereof

INVENTOR(S): Henderson, Daniel R., Palo Alto, CA, UNITED STATES  
Yu, De Chao, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003118555	A1	20030626
APPLICATION INFO.:	US 2002-226820	A1	20020821 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-474699, filed on 29 Dec 1999, GRANTED, Pat. No. US 6495130		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-114262P	19981230 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025	
NUMBER OF CLAIMS:	68	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	57 Drawing Page(s)	
LINE COUNT:	3868	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides adenoviral vectors (preferably replication competent) comprising both an E3 sequence and at least one adenoviral gene under transcriptional control of a target cell-specific transcriptional response element. These vectors display significantly improved cytotoxicity, which is especially useful in the cancer context, in which selective destruction of target cells is desirable. The invention further provides host cells comprising the vectors. The invention further provides methods of using the adenoviral vectors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 11 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:165439 USPATFULL

TITLE: Compositions and methods for delivery of an agent using attenuated Salmonella containing phage

INVENTOR(S): Bermudes, David G., Wallingford, CT, UNITED STATES  
King, Ivan C., North Haven, CT, UNITED STATES  
PATENT ASSIGNEE(S): Clairmont, Caroline A., Cheshire, CT, UNITED STATES  
Vion Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003113293	A1	20030619
APPLICATION INFO.:	US 2002-76117	A1	20020213 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-645418, filed on 24 Aug 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-150928P	19990826 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	2322	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application generally discloses delivery of an agent which can be therapeutic or prophylactic and, more particularly, the preparation and use of attenuated bacteria, such as Salmonella, containing a bacteriophage in which the genome of the bacteriophage has been modified to encode for a gene product of interest, e.g., an antigen or an anti-tumor protein. The bacteria functions as a vector for delivering the bacteriophage encoded gene product of interest to an appropriate site of action, e.g., the site of a solid tumor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 12 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:152945 USPATFULL  
TITLE: Feline immunodeficiency virus gene therapy vectors  
INVENTOR(S): Johnston, Julie C., Wilmington, DE, UNITED STATES  
Sauter, Sybille L., Del Mar, CA, UNITED STATES  
Hsu, David Chi-Tang, San Diego, CA, UNITED STATES  
Sheridan, Philip Lee, San Diego, CA, UNITED STATES  
Hardy, Stephen F., San Francisco, CA, UNITED STATES  
Dubensky, Thomas W., JR., Piedmont, CA, UNITED STATES  
Yee, Jiing-Kuan, Del Mar, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003104611	A1	20030605
APPLICATION INFO.:	US 2001-872696	A1	20010601 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-231235, filed on 15 Jan 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-71731P	19980116 (60)
	US 1998-86825P	19980526 (60)
	US 1999-114955P	19990104 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CHIRON CORPORATION, Intellectual Property, P.O. Box 8097, Emeryville, CA, 94662-8097	
NUMBER OF CLAIMS:	51	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	

LINE COUNT: 5553

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are gene therapy vectors based upon the feline immunodeficiency virus, as well as related packaging cell lines, methods for production, and methods of use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 13 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:133453 USPATFULL

TITLE: Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof

INVENTOR(S): Henderson, Daniel R., Palo Alto, CA, UNITED STATES  
Schoor, Eric R., Palo Alto, CA, UNITED STATES  
Yu, De-Chao, Foster City, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003091538	A1	20030515
APPLICATION INFO.:	US 2002-222479	A1	20020816 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-614495, filed on 11 Jul 2000, GRANTED, Pat. No. US 6436394 Continuation of Ser. No. US 1998-33333, filed on 2 Mar 1998, GRANTED, Pat. No. US 6197293		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-39762P	19970303 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	3434	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells. An adenovirus of the present invention can further comprise a heterologous gene such as a reporter under transcriptional control of a PB-TRE. The adenovirus vectors can be used to detect and monitor samples for the presence of prostate cells as well as to selectively kill malignant cells producing prostate-specific gene products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 14 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:126726 USPATFULL

TITLE: Identification and molecular characterization of proteins, expressed in the Ixodes ricinus salivary glands

INVENTOR(S): Godfroid, Edmond, Brussels, BELGIUM  
Bollen, Alex, Itterbeek, BELGIUM

Leboulle, Gerard, Brussels, BELGIUM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003086937	A1	20030508
APPLICATION INFO.:	US 2002-165605	A1	20020607 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-910430, filed on 19 Jul 2001, PENDING Continuation-in-part of Ser. No. WO 2000-BE61, filed on 6 Jun 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-13425	19990609
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 2040 MAIN STREET, FOURTEENTH FLOOR, IRVINE, CA, 92614	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2275	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a new polynucleotide which encodes a polypeptide expressed in the salivary glands of ticks, more particularly the Ixodes ricinus arthropod tick, during the slow-feeding phase of the blood meal have. This polynucleotide and related polypeptide may be used in different constructions and for different applications which are also included in the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 15 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:106233 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis of pancreatic cancer  
INVENTOR(S): Benson, Darin R., Seattle, WA, UNITED STATES  
Kalos, Michael D., Seattle, WA, UNITED STATES  
Lodes, Michael J., Seattle, WA, UNITED STATES  
Persing, David H., Redmond, WA, UNITED STATES  
Hepler, William T., Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073144	A1	20030417
APPLICATION INFO.:	US 2002-60036	A1	20020130 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-333626P	20011127 (60)
	US 2001-305484P	20010712 (60)
	US 2001-265305P	20010130 (60)
	US 2001-267568P	20010209 (60)
	US 2001-313999P	20010820 (60)
	US 2001-291631P	20010516 (60)
	US 2001-287112P	20010428 (60)
	US 2001-278651P	20010321 (60)
	US 2001-265682P	20010131 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	17	

EXEMPLARY CLAIM: 1  
LINE COUNT: 14253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or **treatment** of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 16 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:78080 USPATFULL  
TITLE: Anti-pathogen system and methods of use thereof  
INVENTOR(S): Dowdy, Steven F., Clayton, MO, UNITED STATES  
PATENT ASSIGNEE(S): Washington University (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003054000	A1	20030320
APPLICATION INFO.:	US 2001-775052	A1	20010201 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-82402P	19980420 (60)
	US 1997-69012P	19971210 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Dike, Bronstein, Roberts & Cushman, Intellectual Property Practice Group, EDWARDS & ANGELL, P.O. Box 9169, Boston, MA, 02209	
NUMBER OF CLAIMS:	86	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	3366	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 17 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:64263 USPATFULL  
TITLE: TISSUE SPECIFIC ADENOVIRAL VECTORS  
INVENTOR(S): HENDERSON, DANIEL R., PALO ALTO, CA, UNITED STATES  
SCHUUR, ERIC R., PALO ALTO, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003044383	A1	20030306
APPLICATION INFO.:	US 1998-151376	A1	19980910 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-699753, filed on 20 Aug 1996, GRANTED, Pat. No. US 5807642		
	Continuation-in-part of Ser. No. US 1995-495034, filed on 27 Jun 1995, GRANTED, Pat. No. US 5698443		
	Continuation-in-part of Ser. No. US 1998-33428, filed on 2 Mar 1998, GRANTED, Pat. No. US 6254862		

Continuation-in-part of Ser. No. US 1998-33555, filed  
on 2 Mar 1998, ABANDONED Continuation-in-part of Ser.  
No. US 1998-33333, filed on 2 Mar 1998, GRANTED, Pat.  
No. US 6197293

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-39597P	19970303 (60)
	US 1997-39763P	19970303 (60)
	US 1997-39762P	19970303 (60)
	US 1997-39599P	19970303 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORRISON AND FOERSTER, 755 PAGE MILL ROAD, PALO ALTO, CA, 943041018	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	44 Drawing Page(s)	
LINE COUNT:	3950	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Host cell specific adenovirus vehicles are provided for transfecting target host cells. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for **treating** neoplasia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 18 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:57096 USPATFULL  
TITLE: Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen  
INVENTOR(S): King, Te Piao, New York, NY, UNITED STATES  
Spangfort, Michael Dho, Viken, SWEDEN  
PATENT ASSIGNEE(S): The Rockefeller University (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003039660	A1	20030227
APPLICATION INFO.:	US 2002-91135	A1	20020304 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-272818P	20010302 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DARBY & DARBY P.C., 805 Third Avenue, New York, NY, 10022	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	7866	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are recombinant hybrid proteins having at least one antigenic peptide sequence introduced into a scaffold protein that retain a native conformation. Also disclosed are recombinant nucleic acids and vectors encoding the hybrid proteins. The hybrid proteins retain immunogenicity but exhibit reduced allergenicity. The hybrid proteins are therefore particularly useful for therapeutic **treatment** of allergy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



L68 ANSWER 19 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:37148 USPATFULL  
TITLE: Adenovirus vectors specific for cells expressing  
carcinoembryonic antigen and methods of use thereof  
INVENTOR(S): Lamparski, Henry, San Mateo, CA, UNITED STATES  
Schoor, Eric R., Palo Alto, CA, UNITED STATES  
Henderson, Daniel R., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003026792	A1	20030206
APPLICATION INFO.:	US 2001-45116	A1	20011023 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-33555, filed on 2 Mar 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-39763P	19970303 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gladys H. Monroy, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	2686	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Replication-competent adenovirus vectors specific for cells expressing carcinoembryonic antigen (CEA), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a CEA transcriptional regulatory element (CEA-TRE). The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one other adenoviral gene under control of another transcriptional regulatory element specific to cells capable of which allow a CEA-TRE to function, such as a variant of a CEA-TRE. By providing for transcriptional initiating regulation dependent upon CEA expression, virus replication can be restricted to target cells which allow a CEA-TRE to function, such as cells expressing CEA, particularly carcinoma cells capable of expressing CEA. An adenovirus of the present invention can further comprise a heterologous gene such as a reporter gene under transcriptional control of a CEA-TRE. The adenovirus vectors can be used to detect and monitor samples for the presence of cells that allow a CEA-TRE to function, as well as to selectively kill malignant cells that allow a CEA-TRE to function.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 20 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:3530 USPATFULL  
TITLE: Functional lentiviral vector from an MLV-based backbone  
INVENTOR(S): Dubensky, Thomas W., JR., Piedmont, CA, UNITED STATES  
Gasmi, Mehdi, San Diego, CA, UNITED STATES  
Sauter, Sybille, Del Mar, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003003565	A1	20030102
APPLICATION INFO.:	US 2001-996073	A1	20011127 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-253419P	20001127 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: CHIRON CORPORATION, Intellectual Property - R440, P.O.  
Box 8097, Emeryville, CA, 94662-8097

NUMBER OF CLAIMS: 30

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 5 Drawing Page(s)

LINE COUNT: 3778

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are gene therapy vectors based on chimeric murine leukemia virus-feline immunodeficiency virus gene therapy vectors which are suitable for a wide variety of gene therapy applications. Also disclosed are related packaging cell lines, methods for production, and methods of use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 21 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:142966 USPATFULL

TITLE: Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene

INVENTOR(S): Barber, Jack R., San Diego, CA, United States

Gruber, Harry E., San Diego, CA, United States

Jolly, Douglas J., Leucadia, CA, United States

PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6569679	B1	20030527
APPLICATION INFO.:	US 1995-471645		19950606 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-155944, filed on 18 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1990-565606, filed on 10 Aug 1990, now abandoned Continuation-in-part of Ser. No. US 1989-395932, filed on 18 Aug 1989, now abandoned Continuation-in-part of Ser. No. US 1988-170515, filed on 21 Mar 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Guzo, David		
ASSISTANT EXAMINER:	Leffers, Jr., Gerald G.		
LEGAL REPRESENTATIVE:	Pochopien, Donald J., Harbin, Alisa A., Blackburn, Robert P.		

NUMBER OF CLAIMS: 24

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 30 Drawing Figure(s); 25 Drawing Page(s)

LINE COUNT: 2735

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides recombinant viral vectors carrying a vector construct which directs the expression of a gene product (e.g., HSVTK) that activates a compound with little or no cytotoxicity into a toxic product. Also provided are methods of destroying or inhibiting pathogenic agents in a warm blooded animal, comprising the step of administering to the animal a viral vector such as that described above, in order to inhibit or destroy the pathogenic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 22 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2003:123418 USPATFULL

TITLE: Chlamydia pneumoniae polynucleotides and uses thereof

INVENTOR(S): Griffais, Remy, Momtrouge, FRANCE

Hoiseth, Susan K., Fairport, NY, United States

Zagursky, Robert John, Victor, NY, United States

Metcalf, Benjamin J., Rochester, NY, United States

Peek, Joel A., Pittsford, NY, United States

PATENT ASSIGNEE(S): Sankaran, Banumathi, Penfield, NY, United States  
Fletcher, Leah Diane, Geneseo, NY, United States  
Genset, S.A., FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6559294	B1	20030506
APPLICATION INFO.:	US 1998-198452		19981123 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1997-14673	19971121
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Borin, Michael	
ASSISTANT EXAMINER:	Zhou, Shubo	
LEGAL REPRESENTATIVE:	Saliwanchik, Lloyd & Saliwanchik	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	8682	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia pneumoniae, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the Chlamydia pneumoniae genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Chlamydia pneumoniae infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides. The invention finally comprises, pharmaceutical, in particular vaccine, compositions for the prevention and/or **treatment** of bacterial, in particular Chlamydia pneumoniae, infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 23 OF 89 USPATFULL on STN  
ACCESSION NUMBER: 2003:67673 USPATFULL  
TITLE: Adenoviral vectors encoding a cytokine and a conditionally lethal gene  
INVENTOR(S): Barber, Jack R., San Diego, CA, United States  
Gruber, Harry E., San Diego, CA, United States  
Jolly, Douglas J., Leucadia, CA, United States  
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6531307	B1	20030311
APPLICATION INFO.:	US 1995-455014		19950531 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-155944, filed on 18 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1993-139994, filed on 20 Oct 1993, now abandoned Continuation of Ser. No. US 1992-965084, filed on 22 Oct 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Guzo, David		

ASSISTANT EXAMINER: Leffers, Jr., Gerald G.  
 LEGAL REPRESENTATIVE: Pochopien, Donald, Harbin, Alisa A., Blackburn, Robert P.  
 NUMBER OF CLAIMS: 23  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 30 Drawing Figure(s); 25 Drawing Page(s)  
 LINE COUNT: 2673

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides recombinant viral vectors carrying a vector construct which directs the expression of a gene product (eg. HSVTK) that activates a compound with little or no cytotoxicity into a toxic product. Also provided are methods of destroying or inhibiting pathogenic agents in a warm blooded animal, comprising the step of administering to the animal a viral vector such as that described above, in order to inhibit or destroy the pathogenic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 24 OF 89 LIFESCI COPYRIGHT 2003 CSA on STN

ACCESSION NUMBER: 2003:42364 LIFESCI  
 TITLE: Antiviral ricin-like proteins  
 AUTHOR: Borgford, T.  
 CORPORATE SOURCE: Twinstrand Therapeutics Inc.  
 SOURCE: (20030311) . US Patent: 6531125; US CLASS: 424/94.3; 424/94.1; 530/350; 530/370; 514/2; 536/23.2; 536/23.4; 536/23.6; 435/320.1.  
 DOCUMENT TYPE: Patent  
 FILE SEGMENT: W3; V  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English

AB The present invention provides a protein having an A chain of a **ricin**-like toxin, a B chain of a **ricin**-like toxin and a heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a retroviral **protease** such as HIV or an HTLV **protease**. The invention also relates to a nucleic acid molecule encoding the protein and to expression vectors incorporating the nucleic acid molecule. Also provided is a method of inhibiting or destroying mammalian cells infected with a retrovirus utilizing the proteins of the invention; and **pharmaceutical compositions for treating HIV** infections and human T-cell leukemias involving HTLV.

L68 ANSWER 25 OF 89 USPATFULL on STN DUPLICATE 4

ACCESSION NUMBER: 2002:294756 USPATFULL  
 TITLE: Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof  
 INVENTOR(S): Little, Andrew S., Balboa Island, CA, UNITED STATES  
 Henderson, Daniel R., Palo Alto, CA, UNITED STATES  
 Schuur, Eric R., Palo Alto, CA, UNITED STATES  
 Lamparski, Henry, San Mateo, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002164799	A1	20021107
	US 6585968	B2	20030701
APPLICATION INFO.:	US 2001-898883	A1	20010702 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-593308, filed on 13 Jun 2000, ABANDONED Continuation of Ser. No. US 1998-33428, filed on 2 Mar 1998, GRANTED, Pat. No. US 6254862		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-39597P	19970303 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: BOZICEVIC FIELD & FRANCIS LLP, Suite 200, 200  
Middlefield Road, Menlo Park, CA, 94025  
NUMBER OF CLAIMS: 48  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 23 Drawing Page(s)  
LINE COUNT: 2729

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Adenovirus vectors replication specific for cells expressing .alpha.-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 26 OF 89 USPATFULL on STN  
ACCESSION NUMBER: 2002:344434 USPATFULL  
TITLE: Tissue-specific enhancer active in prostate  
INVENTOR(S): Henderson, Daniel R., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198164	A1	20021226
APPLICATION INFO.:	US 2001-861682	A1	20010521 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-448321, filed on 23 Nov 1999, ABANDONED Continuation of Ser. No. US 1997-891581, filed on 11 Jul 1997, GRANTED, Pat. No. US 6136792 Continuation of Ser. No. US 1995-380916, filed on 30 Jan 1995, GRANTED, Pat. No. US 5648478 Continuation-in-part of Ser. No. US 1994-182247, filed on 13 Jan 1994, GRANTED, Pat. No. US 5830686		

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: BOZICEVIC FIELD & FRANCIS LLP, Suite 200, 200  
Middlefield Road, Menlo Park, CA, 94025  
NUMBER OF CLAIMS: 20  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 18 Drawing Page(s)  
LINE COUNT: 1550

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a human prostate-specific transcriptional regulatory sequence, polynucleotide comprising such regulatory regions, toxin gene constructs wherein a toxin gene is expressed under the transcriptional control of a human prostate-specific transcriptional regulatory sequence, and methods for **treating** prostate disease using such toxin gene constructs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 27 OF 89 USPATFULL on STN  
ACCESSION NUMBER: 2002:272801 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis of colon cancer  
INVENTOR(S): Stolk, John A., Bothell, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Chenault, Ruth A., Seattle, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2002150922 A1 20021017  
 APPLICATION INFO.: US 2001-998598 A1 20011116 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-304037P	20010710 (60)
	US 2001-279670P	20010328 (60)
	US 2001-267011P	20010206 (60)
	US 2000-252222P	20001120 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 17  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 9233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or **treatment** of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 28 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:258856 USPATFULL  
 TITLE: 33945, a human glycosyltransferase family member and uses therefor  
 INVENTOR(S): Olandt, Peter J., East Boston, MA, UNITED STATES  
 Meyers, Rachel E., Newton, MA, UNITED STATES  
 Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002142426	A1	20021003
APPLICATION INFO.:	US 2002-74527	A1	20020212 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-269202P	20010215 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Jean M. Silveri, Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA, 02139	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	4739	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 33945 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33945 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33945 gene has been introduced or disrupted. The invention still further provides isolated 33945 proteins, fusion proteins, antigenic peptides and anti-33945 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 29 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:250769 USPATFULL  
TITLE: Human glandular kallikrein enhancer, vectors comprising  
the enhancer and methods of use thereof  
INVENTOR(S): Yu, De Chao, Foster City, CA, UNITED STATES  
Henderson, Daniel R., Palo Alto, CA, UNITED STATES  
Schuur, Eric R., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002136707	A1	20020926
APPLICATION INFO.:	US 2001-875228	A1	20010605 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-127834, filed on 3 Aug 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-54523P	19970804 (60)
	US 1998-76545P	19980302 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOZICEVIC FIELD & FRANCIS LLP, Suite 200, 200 Middlefield Road, Menlo Park, CA, 94025	
NUMBER OF CLAIMS:	83	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	33 Drawing Page(s)	
LINE COUNT:	4568	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Enhancers which preferentially increase the transcription of cis-linked coding sequences in prostate cells are provided. Methods of using DNA constructs comprising the enhancers to control transcription of heterologous polynucleotides are also provided. Delivery vehicles comprising the enhancers and methods of using the vehicles are also provided. Adenovirus vectors in which one or more genes are under transcriptional control of the enhancers of the invention are also provided. Further provided are methods of using the adenovirus vectors of the invention to confer selective cytotoxicity in mammalian cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 30 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:243051 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis  
of ovarian cancer  
INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES  
Jones, Robert, Seattle, WA, UNITED STATES  
Harlocker, Susan L., Seattle, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132237	A1	20020919
APPLICATION INFO.:	US 2001-867701	A1	20010529 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	11	

EXEMPLARY CLAIM: 1  
LINE COUNT: 25718

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or **treatment** of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 31 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:242791 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis of colon cancer  
INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Secrist, Heather, Seattle, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002131971	A1	20020919
APPLICATION INFO.:	US 2001-33528	A1	20011226 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223283P	20000803 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8083	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or **treatment** of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 32 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:235052 USPATFULL  
TITLE: Identification and molecular characterization of proteins, expressed in the Ixodes ricinus salivary glands  
INVENTOR(S): Godfroid, Edward, Brussels, BELGIUM  
Bollen, Alex, Itterbeek, BELGIUM  
Leboulle, Gerard, Brussels, BELGIUM



	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002127235	A1	20020912
APPLICATION INFO.:	US 2001-910430	A1	20010719 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-BE61, filed on 6 Jun 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1999-13425	19990609
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	2508	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to new polynucleotides which encode polypeptides expressed in the salivary glands of ticks, more particularly the Ixodes ricinus arthropod tick, during the slow-feeding phase of the blood meal have. Said polynucleotides and related polynucleotides may be used in different constructions and for different applications which are also included in said invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 33 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:221972 USPATFULL  
 TITLE: Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising uroplakin-specific transcriptional regulatory sequences, and methods of use thereof  
 INVENTOR(S): Yu, De-Chao, Foster City, CA, UNITED STATES  
 Zhang, Hong, Cupertino, CA, UNITED STATES  
 Henderson, Daniel R., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002120117	A1	20020829
APPLICATION INFO.:	US 2001-814292	A1	20010321 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-191861P	20000324 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Debra J. Glaister, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018	
NUMBER OF CLAIMS:	103	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	27 Drawing Page(s)	
LINE COUNT:	4484	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides new urothelial cell specific transcriptional regulatory sequences derived from human uroplakin II (hUPII), as well as polynucleotide constructs such as adenoviral vectors and methods of using hUPII-derived TRES. Additionally, the invention provides adenoviral vectors comprising a gene, preferably an adenovirus gene, under transcriptional control of a urothelial cell-specific transcriptional regulatory element (TRE). These vectors display urothelial cell-specific cytotoxicity, which is especially useful in the context of bladder cancer, in which destruction of these cells is desirable. The invention further provides compositions and host cells

comprising the vectors, as well as method of using the adenoviral vectors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 34 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:133502 USPATFULL  
TITLE: Feline immunodeficiency virus gene therapy vectors  
INVENTOR(S): Johnston, Julie C., Hockessin, DE, UNITED STATES  
Sauter, Sybille L., Del Mar, CA, UNITED STATES  
Hsu, David Chi-Tang, San Diego, CA, UNITED STATES  
Sheridan, Philip Lee, San Diego, CA, UNITED STATES  
Hardy, Stephen F., San Francisco, CA, UNITED STATES  
Dubensky, Thomas W., JR., Piedmont, CA, UNITED STATES  
Yee, Jiing-Kuan, Arcadia, CA, UNITED STATES  
PATENT ASSIGNEE(S): CHIRON CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002068354	A1	20020606
APPLICATION INFO.:	US 2001-797518	A1	20010301 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-231235, filed on 15 Jan 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-71731P	19980116 (60)
	US 1998-86825P	19980526 (60)
	US 1999-114955P	19990104 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CHIRON CORPORATION, Intellectual Property - R 440, P. O. Box 8097, Emeryville, CA, 94662-8097	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	5809	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are gene therapy vectors based upon the feline immunodeficiency virus, as well as related packaging cell lines, methods for production, and methods of use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 35 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:133200 USPATFULL  
TITLE: Tissue specific adenoviral vectors  
INVENTOR(S): Henderson, Daniel R., Palo Alto, CA, UNITED STATES  
Schuur, Eric R., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002068049	A1	20020606
APPLICATION INFO.:	US 2000-732169	A1	20001206 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-151376, filed on 10 Sep 1998, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Linda R. Judge, CELL GENESYS Inc., 342 Lakeside Drive, Foster City, CA, 94404		
NUMBER OF CLAIMS:	54		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	44 Drawing Page(s)		
LINE COUNT:	3956		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Host cell specific adenovirus vehicles are provided for transfecting target host cells. By providing for transcriptional initiating regulation dependent upon transcription factors that are only active in specific, limited cell types, virus replication will be restricted to the target cells. The modified adenovirus may be used as a vehicle for introducing new genetic capability, particularly associated with cytotoxicity for **treating** neoplasia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 36 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:105967 USPATFULL  
TITLE: Complex for transferring an anionic substance of interest into a cell  
INVENTOR(S): Rittner, Karola, Strasbourg, FRANCE  
Jacobs, Eric, Stotheim, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002055174	A1	20020509
APPLICATION INFO.:	US 2001-865553	A1	20010529 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2000-440162	20000526
	EP 2001-440049	20010227
	US 2000-246083P	20001107 (60)
	US 2001-277982P	20010323 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	30 Drawing Page(s)	
LINE COUNT:	1919	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A peptide and a related complex for transferring an anionic substance of interest into a cell are disclosed wherein said peptide is a cationic peptide capable of binding to an anionic substance, capable to cause membrane disruption and which does not comprise acidic amino acid, preferably glutamic amino acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 37 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:92287 USPATFULL  
TITLE: FELINE IMMUNODEFICIENCY VIRUS GENE THERAPY VECTORS  
INVENTOR(S): JOHNSTON, JULIE C., WILMINGTON, DE, UNITED STATES  
SAUTER, SYBILLE L., DEL MAR, CA, UNITED STATES  
HSU, DAVID CHI-TANG, SAN DIEGO, CA, UNITED STATES  
SHERIDAN, PHILIP LEE, SAN DIEGO, CA, UNITED STATES  
HARDY, STEPHEN F., SAN FRANCISCO, CA, UNITED STATES  
DUBENSKY, THOMAS W., JR., PIEDMONT, CA, UNITED STATES  
YEE, JIING-KUAN, DEL MAR, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002048805	A1	20020425
APPLICATION INFO.:	US 1999-231235	A1	19990115 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-71731P	19980116 (60)
	US 1998-86825P	19980526 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: Chiron Corporation, Intellectual Property - R440, P.O.  
Box 8097, Emeryville, CA, 94662-8097  
NUMBER OF CLAIMS: 51  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 4 Drawing Page(s)  
LINE COUNT: 5499  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Disclosed are gene therapy vectors based upon the feline  
immunodeficiency virus, as well as related packaging cell lines, methods  
for production, and methods of use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 38 OF 89 USPATFULL on STN  
ACCESSION NUMBER: 2002:85168 USPATFULL  
TITLE: RECOMBINANT FUSION PROTEINS BASED ON  
RIBOSOME-INACTIVATING PROTEINS OF THE MISTLETOE VISCUM  
ALBUM  
INVENTOR(S): ECK, JURGEN, HEPPENHEIM, GERMANY, FEDERAL REPUBLIC OF  
SCHMIDT, ARNO, BUTTELBOHN, GERMANY, FEDERAL REPUBLIC OF  
ZINKE, HOLGER, BICKENBACH, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002045208	A1	20020418
APPLICATION INFO.:	US 1999-347064	A1	19990702 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1998-EP9, filed on 2 Jan 1998, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	AKIN, GUMP, STRAUSS, HAUER & FELD, L.L.P., ONE COMMERCE SQUARE, 2005 MARKET STREET, SUITE 2200, PHILADELPHIA, PA, 19103		
NUMBER OF CLAIMS:	46		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	36 Drawing Page(s)		
LINE COUNT:	3070		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention relates to nucleic acid molecules which encode fusion  
proteins which contain as components at least one effector module, a  
processing module and a targeting module. The nucleic acid molecules  
according to the invention preferably also encode a modulator module  
and/or an affinity module. The invention furthermore relates to vectors  
containing these nucleic acid molecules, hosts transformed with the  
vectors according to the invention, fusion proteins encoded by nucleic  
acids according to the invention or produced by the hosts according to  
the invention as well as to medicaments containing the polypeptides or  
vectors according to the invention. These medicaments are particularly  
significant for the therapy of diseases associated with a pathological  
reproduction and/or increased activity of cell populations. A temporary,  
periodic and strong proliferation, infiltration and immune activity of  
cells of the immune system is found in autoimmune diseases and  
allergies, the specificity of these immune cells being due to their  
reaction to a particular antigen or allergen. These medicaments may also  
be advantageously used for **treating** tumors. The polypeptides  
and vectors described in the present invention may be used to develop  
medicaments and to test toxin activity-modulating factors. The invention  
thus also concerns corresponding processes, uses and kits. The modules,  
with the exception of the affinity and the targeting module, are  
preferably encoded by nucleic acids extracted or derived from the  
mistletoe lectin proprotein coding sequence.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 39 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:42943 USPATFULL  
TITLE: Bone sialoprotein based toxic gene therapy for the  
**treatment** of calcified tumors and tissues  
INVENTOR(S): Koeneman, Kenneth S., Charlottesville, VA, UNITED  
STATES  
Chung, Leland W.K., Lovington, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002025307	A1	20020228
APPLICATION INFO.:	US 2001-884098	A1	20010620 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1999-US30642, filed on 22 Dec 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-113200P	19981222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	
LINE COUNT:	3619	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to promoters, enhancers and other regulatory elements that direct expression within tumor and tissue cells with calcification potential. In particular, it relates to compositions comprising nucleotide sequences from the 5' regulatory region, and transcriptionally active fragments thereof, that control expression of a bone sialoprotein ("BSP"). Specifically provided are expression vectors, host cells and transgenic animals wherein a BSP regulatory region is capable of controlling expression of a heterologous coding sequence, over-expressing an endogenous BSP coding sequence or an inhibitor of a pathological process or knocking out expression of a specific gene believed to be important for a calcification-related disease in tumor and tissue cells with calcification potential. The invention also relates to methods for using said vectors, cells and animals for screening candidate molecules for agonists and antagonists of disorders involving tumor and tissue cells with calcification potential. The present invention further relates to compositions and methods for modulating expression of compounds within tumor and tissue cells with calcification potential. Methods for using molecules and compounds identified by screening assays for therapeutic **treatments** also are provided. The invention further relates to methods of **treating** tumors and other diseases and disorders involving tumor and tissue cells with calcification potential.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 40 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:32230 USPATFULL  
TITLE: Chimeric adenoviral vectors  
INVENTOR(S): Lusky, Monika, Freiburg, GERMANY, FEDERAL REPUBLIC OF  
Winter, Arend Jan, Strasbourg, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019051	A1	20020214
APPLICATION INFO.:	US 2001-867475	A1	20010531 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-463486, filed on 27 Jan 2000, PENDING		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	FR 1998-6654	19980527
	WO 1999-FR1238	19990527
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	2525	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The invention concerns adenoviral vectors having the characteristic of containing a region essential for heterologous packaging with respect to the adenoviral genome from which they are derived. The invention also concerns a method for making a viral preparation containing said adenoviral vectors, a cell, a **pharmaceutical composition** or material comprising them and their therapeutic or prophylactic use. Finally, the invention concerns an adenoviral genome of animal origin having attenuated packaging properties with respect to the native genome from which it is derived.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 41 OF 89 USPATFULL on STN  
 ACCESSION NUMBER: 2002:12021 USPATFULL  
 TITLE: In VIVO loading of MHC  
 INVENTOR(S): Roberts, Bruce L., Southboro, MA, UNITED STATES  
 Shankara, Srinivas, Shrewsbury, MA, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2002006397	A1	20020117
APPLICATION INFO.:	US 2001-843342	A1	20010425 (9)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2000-200562P	20000428 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENZYME CORPORATION, LEGAL DEPARTMENT, 15 PLEASANT ST CONNECTOR, FRAMINGHAM, MA, 01701-9322	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2349	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention provides several embodiments that ultimately result in the in vivo loading of endogenous antigenic peptides from a target cell. The invention also presents a method for inducing an immune response to an endogenous antigen in a subject by delivering an effective amount of an agent that stimulates in vivo loading of the endogenous antigen into an Antigenic Peptide Binding Protein ("APBP"). The APBP presents the endogenous antigen to a T cell in vivo. A polynucleotide encoding an APBP is delivered to a target cell under conditions such that the APBP is expressed in the target cell. Endogenous antigenic peptides bind the APBP forming an APBP:peptide complex. A cytotoxic agent also is administered to the subject and delivered to the target cell in an amount effective to lyse the target cell which releases the complexes. The complexes present the antigenic peptide to a T cell or an antigen presenting cell (APC) which mounts the immune response. An effective amount of an antigen presenting cell (APC) recruitment factor can be administered to the subject to recruit APC to the locus of the target cell. APCs take up the APBP:peptide complexes

and the peptides are processed and presented by MHC molecules to T cells in vivo.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 42 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:332612 USPATFULL  
TITLE: Chimeric gene constructs  
INVENTOR(S): Gruber, Harry E., P.O. Box 675272, Rancho Santa Fe, CA, United States 92067  
Jolly, Douglas J., 277 Hillcrest Dr., Leucadia, CA, United States 92024  
Respass, James G., 4966 Lamont St., San Diego, CA, United States 92109  
Laikind, Paul K., 3370 Goldfinch St., San Diego, CA, United States 92103

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495349	B1	20021217
APPLICATION INFO.:	US 1995-462512		19950605 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-136739, filed on 12 Oct 1993, now patented, Pat. No. US 5716826 Continuation of Ser. No. US 1989-395932, filed on 18 Aug 1989, now abandoned Continuation-in-part of Ser. No. US 1988-170515, filed on 21 Mar 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Guzo, David		
LEGAL REPRESENTATIVE:	Pochopien, Donald, Dollard, Anne S., Blackburn, Robert P.		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	31 Drawing Figure(s); 27 Drawing Page(s)		
LINE COUNT:	3215		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and **pharmaceutical compositions** containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 43 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:332464 USPATFULL  
TITLE: Target cell-specific adenoviral vectors containing E3 and methods of use thereof  
INVENTOR(S): Henderson, Daniel R., Palo Alto, CA, United States  
Yu, De Chao, Foster City, CA, United States  
PATENT ASSIGNEE(S): Calydon, Inc., Sunnyvale, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495130	B1	20021217
APPLICATION INFO.:	US 1999-474699		19991229 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-114262P	19981230 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Ketter, James	
ASSISTANT EXAMINER:	Li, Janice	
LEGAL REPRESENTATIVE:	Judge, Esq., Linda, Sherwood, Pamela J., Bozicevic, Field & Francis LLP	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	60 Drawing Figure(s); 57 Drawing Page(s)	
LINE COUNT:	4028	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides adenoviral vectors (preferably replication competent) comprising both an E3 sequence and at least one adenoviral gene under transcriptional control of a target cell-specific transcriptional response element. These vectors display significantly improved cytotoxicity, which is especially useful in the cancer context, in which selective destruction of target cells is desirable. The invention further provides host cells comprising the vectors. The invention further provides methods of using the adenoviral vectors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 44 OF 89 USPATFULL on STN  
 ACCESSION NUMBER: 2002:297458 USPATFULL  
 TITLE: Chimeric adenoviral vectors  
 INVENTOR(S): Mehtali, Majid, Amsterdam, NETHERLANDS  
 Lusk, Monika, Frieberg, GERMANY, FEDERAL REPUBLIC OF  
 Winter, Arend Jan, Strasbourg, FRANCE  
 PATENT ASSIGNEE(S): Transgene S. A., Strasbourg, FRANCE (non-U.S.  
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6479290	B1	20021112
	WO 9961638		19991202
APPLICATION INFO.:	US 2000-463486		20000127 (9)
	WO 1999-FR1238		19990527

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1998-6654	19980527
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Guzo, David	
ASSISTANT EXAMINER:	Leffers, Jr., Gerald G.	
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	1196	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns adenoviral vectors having the characteristic of containing a region essential for heterologous packaging with respect to the adenoviral genome from which they are derived. The invention also concern a method for making a viral preparation containing said adenoviral vectors, a cell, a **pharmaceutical composition** or material comprising them and their therapeutic or prophylactic use. Finally, the invention concerns an adenoviral genome of animal origin having attenuated packaging properties with respect to the native genome from which it is derived.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.



L68 ANSWER 45 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:268880 USPATFULL  
TITLE: Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis  
INVENTOR(S): Dubensky, Jr., Thomas W., Del Mod, CA, United States  
Polo, John M., Encinitas, CA, United States  
Belli, Barbara A., San Diego, CA, United States  
Schlesinger, Sondra, St. Louis, MO, United States  
Dryga, Sergey A., Fort Collins, CO, United States  
Frolov, Ilya, St. Louis, MO, United States  
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
Washington University, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6465634	B1	20021015
APPLICATION INFO.:	US 1999-415900		19991008 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-944645, filed on 6 Oct 1997 Continuation-in-part of Ser. No. US 1997-833148, filed on 4 Apr 1997, now abandoned Continuation-in-part of Ser. No. US 1996-679640, filed on 12 Jul 1996, now abandoned Continuation-in-part of Ser. No. US 1996-668953, filed on 24 Jun 1996, now abandoned Continuation-in-part of Ser. No. US 1996-628594, filed on 5 Apr 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Wortman, Donna C.		
LEGAL REPRESENTATIVE:	Dollard, Anne S., Blackburn, Robert P., Pasternak, Dahna		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	68 Drawing Figure(s); 63 Drawing Page(s)		
LINE COUNT:	8244		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 46 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:254196 USPATFULL  
TITLE: Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis  
INVENTOR(S): Dubensky, Jr., Thomas W., Del Mar, CA, United States  
Polo, John M., Encinitas, CA, United States  
Belli, Barbara A., San Diego, CA, United States  
Schlesinger, Sondra, St. Louis, MO, United States  
Dryga, Sergey A., Fort Collins, CO, United States  
Frolov, Ilva, St. Louis, MO, United States  
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
Washington University, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6458560	B1	20021001
APPLICATION INFO.:	US 1999-415868		19991008 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-944645, filed on 6 Oct 1997 Continuation-in-part of Ser. No. US 1997-833148, filed on 4 Apr 1997, now abandoned Continuation-in-part of Ser. No. US 1996-679640, filed on 12 Jul 1996, now abandoned Continuation-in-part of Ser. No. US 1996-668953, filed on 24 Jun 1996, now abandoned Continuation-in-part of Ser. No. US 1996-628594, filed on 5 Apr 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Wortman, Donna C.		
LEGAL REPRESENTATIVE:	Dollard, Anne S., Cullman, Louis C., Blackburn, Robert P.		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	68 Drawing Figure(s); 63 Drawing Page(s)		
LINE COUNT:	8154		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 47 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:238871 USPATFULL  
 TITLE: Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis  
 INVENTOR(S): Dubensky, Jr., Thomas W., Del Mar, CA, United States  
 Polo, John M., Encinitas, CA, United States  
 Belli, Barbara A., San Diego, CA, United States  
 Schlesinger, Sondra, St. Louis, MO, United States  
 Dryga, Sergey A., Fort Collins, CO, United States  
 Frolov, Ilya, St. Louis, MO, United States  
 PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
 Washington University, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6451592	B1	20020917
APPLICATION INFO.:	US 1997-944465		19971006 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-833148, filed on 4 Apr 1997, now abandoned Continuation-in-part of Ser. No. US 1996-679640, filed on 12 Jul 1996, now abandoned Continuation-in-part of Ser. No. US 1996-668953, filed on 24 Jun 1996, now abandoned Continuation-in-part of Ser. No. US 1996-628594, filed on 5 Apr 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Wortman, Donna C.		

LEGAL REPRESENTATIVE: Dollard, Anne S., Cullman, Louis C., Blackburn, Robert P.  
NUMBER OF CLAIMS: 26  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 68 Drawing Figure(s); 63 Drawing Page(s)  
LINE COUNT: 8461

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 48 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:209108 USPATFULL

TITLE: Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof  
INVENTOR(S): Henderson, Daniel R., Palo Alto, CA, United States  
Schuur, Eric R., Palo Alto, CA, United States  
Yu, De-Chao, Foster City, CA, United States

PATENT ASSIGNEE(S): Cell Genesys, Inc., Foster City, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6436394	B1	20020820
APPLICATION INFO.:	US 2000-614495		20000711 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-33333, filed on 2 Mar 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-39762P	19970303 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Guzo, David	
LEGAL REPRESENTATIVE:	Judge, Esq., Linda, Sherwood, Pamela J., Bozicevic, Field & Francis LLP	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 11 Drawing Page(s)	
LINE COUNT:	3618	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcription regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells. An adenovirus of the present invention can further comprise a heterologous gene such as a reporter under transcriptional control of a PB-TRE. The adenovirus

vectors can be used to detect and monitor samples for the presence of prostate cells as well as to selectively kill malignant cells producing prostate-specific gene products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 49 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:201895 USPATFULL

TITLE: Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same

INVENTOR(S): Henderson, Daniel R., Palo Alto, CA, United States  
Yu, De-Chao, Foster City, CA, United States

PATENT ASSIGNEE(S): Cell Genesys, Inc., Foster City, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6432700	B1	20020813
APPLICATION INFO.:	US 1998-33556		19980302 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-39597P	19970303 (60)
	US 1997-39762P	19970303 (60)
	US 1997-39763P	19970303 (60)
	US 1997-54523P	19970804 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Stucker, Jeffrey

ASSISTANT EXAMINER: Winkler, Ulrike

LEGAL REPRESENTATIVE: Judge, Linda R., Sherwood, Pamela J., Bozicevic, Field & Francis LLP

NUMBER OF CLAIMS: 17

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 16 Drawing Figure(s); 15 Drawing Page(s)

LINE COUNT: 3724

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Replication-competent adenovirus vectors specific for target cells and methods of use of such viruses are provided. These adenoviruses comprise a first adenoviral gene under control of a cell specific heterologous (i.e., non-adenoviral) transcriptional regulatory element (TRE) and at least a second gene under control of a second heterologous TRE, where the heterologous TREs are different from each other in polynucleotide sequence but functional in the same cell. The adenoviral gene can be, for example, a gene required for adenoviral replication. The second gene can be, for example, a second adenoviral gene or a transgene, such as a gene which can contribute to cytotoxicity in the target cell. Adenoviral replication can be restricted to target cells in which the heterologous TREs are functional and thus, the adenovirus vectors can provide selective cytotoxicity to the target cells, particularly neoplastic cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 50 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:188229 USPATFULL

TITLE: Alphavirus structural protein expression cassettes

INVENTOR(S): Dubensky, Jr., Thomas W., Piedmont, CA, United States  
Polo, John M., Encinitas, CA, United States  
Schlesinger, Sondra, St. Louis, MO, United States  
Frolov, Ilya, St. Louis, MO, United States

PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
Washington University, St. Louis, MO, United States

(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6426196	B1	20020730
APPLICATION INFO.:	US 1999-415785		19991008 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-944465, filed on 6 Oct 1997 Continuation-in-part of Ser. No. US 1997-833148, filed on 4 Apr 1997, now abandoned Continuation-in-part of Ser. No. US 1996-679640, filed on 12 Jul 1996, now abandoned Continuation-in-part of Ser. No. US 1996-668953, filed on 24 Jun 1996, now abandoned Continuation-in-part of Ser. No. US 1996-628594, filed on 5 Apr 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Wortman, Donna C.		
LEGAL REPRESENTATIVE:	Blackburn, Robert P., Pasternak, Dahna, Dollard, Anne S.		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	68 Drawing Figure(s); 63 Drawing Page(s)		
LINE COUNT:	8254		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Isolated nucleic acid molecules are disclosed. comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 51 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:152470 USPATFULL  
TITLE: Method for inhibiting human tumor cells  
INVENTOR(S): Gruber, Harry E., San Diego, CA, United States  
Jolly, Douglas J., La Jolla, CA, United States  
Respass, James G., San Diego, CA, United States  
Laikind, Paul K., San Diego, CA, United States  
Barber, Jack R., San Diego, CA, United States  
St. Louis, Daniel C., Rockville, MD, United States  
Chada, Sunil D., Vista, CA, United States  
Chang, Stephen M. W., San Diego, CA, United States  
Warner, John F., San Diego, CA, United States  
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6410326	B1	20020625
APPLICATION INFO.:	US 1995-486683		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-344743, filed on 23 Nov 1994 Continuation of Ser. No. US 1993-139994, filed on 20 Oct 1993, now abandoned Continuation of Ser. No. US 1992-965084, filed on 22 Oct 1992, now abandoned Continuation of Ser. No. US 1990-586603, filed on 21 Sep 1990, now abandoned Continuation-in-part of Ser. No. US 1990-565606, filed on 10 Aug 1990, now abandoned Continuation-in-part of Ser. No. US 1989-395932, filed on 18 Aug 1989, now abandoned Continuation-in-part of		

Ser. No. US 1988-170515, filed on 21 Mar 1988, now abandoned

DOCUMENT TYPE: Utility  
 FILE SEGMENT: GRANTED  
 PRIMARY EXAMINER: Yucel, Remy  
 LEGAL REPRESENTATIVE: Blackburn, Robert P., Pochopien, Donald, Dollard, Anne S.  
 NUMBER OF CLAIMS: 10  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 54 Drawing Figure(s); 44 Drawing Page(s)  
 LINE COUNT: 4484  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and **pharmaceutical compositions** containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 52 OF 89 USPATFULL on STN  
 ACCESSION NUMBER: 2002:116068 USPATFULL  
 TITLE: Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis  
 INVENTOR(S): Dubensky, Jr., Thomas W., Del Mon, CA, United States  
 Polo, John M., Encinitas, CA, United States  
 Belli, Barbara A., San Diego, CA, United States  
 Schlesinger, Sondra, St. Louis, MO, United States  
 Dryga, Sergey A., Fort Collins, CO, United States  
 Frolov, Ilya, St. Louis, MO, United States  
 PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)  
 Washington University, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6391632	B1	20020521
APPLICATION INFO.:	US 1999-415784		19991008 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-944465, filed on 6 Oct 1997 Continuation-in-part of Ser. No. US 1997-833148, filed on 4 Apr 1997, now abandoned Continuation-in-part of Ser. No. US 1996-679640, filed on 12 Jul 1996, now abandoned Continuation-in-part of Ser. No. US 1996-668953, filed on 24 Jun 1996, now abandoned Continuation-in-part of Ser. No. US 1996-628594, filed on 5 Apr 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Wortman, Donna C.		
LEGAL REPRESENTATIVE:	Dollard, Anne S., Cullman, Louis C., Blackburn, Robert P.		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	68 Drawing Figure(s); 63 Drawing Page(s)		
LINE COUNT:	8166		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Isolated nucleic acid molecules are disclosed, comprising an alphavirus		

nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as is compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 53 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:88256 USPATFULL  
TITLE: Recombinant alphavirus particles  
INVENTOR(S): Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United States  
Polo, John M., San Diego, CA, United States  
Ibanez, Carlos E., San Diego, CA, United States  
Driver, David A., San Diego, CA, United States  
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6376236	B1	20020423
APPLICATION INFO.:	US 1999-236140		19990122 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-404796, filed on 15 Mar 1995, now patented, Pat. No. US 6015686 Continuation-in-part of Ser. No. US 1995-376184, filed on 18 Jan 1995, now abandoned Continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned Continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Brusca, John S.		
LEGAL REPRESENTATIVE:	McMasters, David D., Dollard, Anne S., Blackburn, Robert P.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	37 Drawing Figure(s); 30 Drawing Page(s)		
LINE COUNT:	9308		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are recombinant alphavirus particles comprising a) an alphavirus vector construct which directs the expression of a heterologous nucleic acid molecule; b) a capsid protein; and c) an envelope glycoprotein from a virus different from said alphavirus vector.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 54 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2002:19196 USPATFULL  
TITLE: Eukaryotic layered vector initiation systems for production of recombinant proteins  
INVENTOR(S): Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United States  
Polo, John M., San Diego, CA, United States  
Driver, David A., San Diego, CA, United States  
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6342372	B1	20020129
APPLICATION INFO.:	US 1999-350399		19990708 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-931783, filed on 16 Sep 1997, now abandoned Division of Ser. No. US 1995-404796, filed on 15 Mar 1995, now patented, Pat. No. US 6015686 Continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned Continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned Continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned Continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Brusca, John S.		
LEGAL REPRESENTATIVE:	McMasters, David D., Dollard, Anne S., Blackburn, Robert P.		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	37 Drawing Figure(s); 30 Drawing Page(s)		
LINE COUNT:	10217		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 55 OF 89 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN

ACCESSION NUMBER: 2003-156950 [15] WPIDS

CROSS REFERENCE: 2003-148773 [14]

DOC. NO. CPI: C2003-040841

TITLE: Composition for **treating** tumors and their metastases to bone, comprises agent that binds to bone sialoprotein in serum or plasma.

DERWENT CLASS: B04 D16

INVENTOR(S): ARMBRUSTER, F P; BERGER, M R; FORSMANN, U J; KARMATSCHEK, M; NADER, W F; PAULSSON, M

PATENT ASSIGNEE(S): (OSTE-N) OSTEOPEP PHARMA GMBH

COUNTRY COUNT: 100

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002100899	A2	20021219	(200315)*	GE	45
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ					
NL OA PT SD SE SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK					
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR					
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT					
RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM					
ZW					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002100899	A2	WO 2002-EP6456	20020612

PRIORITY APPLN. INFO: DE 2001-10128639 20010615; EP 2001-114388 20010613



AN 2003-156950 [15] WPIDS  
CR 2003-148773 [14]  
AB WO2002100899 A UPAB: 20030303

NOVELTY - **Pharmaceutical composition** (A) against tumors and their metastases, particularly those that colonize bone, comprising as active ingredient at least one agent (I) that binds to bone sialoprotein (BSP), or its fragments, in serum or plasma, is new.

ACTIVITY - Cytostatic.

Nude mice were injected with BSP-expressing MDA-MB 231 breast cancer cells, and when bone metastases had developed, the animals were given weekly subcutaneous injections of 10 mg/kg of antibodies specific for tumor-derived BSP. In one animal, a single metastasis in the distal femur was cured 42 days after starting **treatment**.

MECHANISM OF ACTION - (I) bind to, and neutralize, circulating BSP (either free or bound to factor H), so the protective effect of binding to factor H against complement activation is lost, and the tumor cells become accessible to the immune system. The angiogenic effect of BSP is also eliminated.

USE - (A) is used to **treat** tumors of the prostate, breast, lung, kidney, or thyroid; of the blood, lymphatic, cardiovascular, nervous, respiratory or endocrine systems; of the respiratory, digestive and urogenital tracts, and of the skin. Also (not claimed), (I), when coupled to a radionuclide, can be used for localization and monitoring of bone metastases by immunoscintigraphy.

ADVANTAGE - (I) are specific for the tumor-derived isoform of BSP (this folds in a different way from the native isoform, so exposes different epitopes), so lack the side effects associated with use of antibodies against the normal isoform.

Dwg.0/5

L68 ANSWER 56 OF 89 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN  
ACCESSION NUMBER: 2003-221280 [21] WPIDS  
DOC. NO. CPI: C2003-056061  
TITLE: Novel conjugate useful for **treating**  
cell-surface protease-associated disease, comprises a  
therapeutic agent and a peptidic or nucleic acid  
substrate linked to it optionally by a peptidic linker.  
DERWENT CLASS: B04 B05 D16  
INVENTOR(S): KEMP, S J; KOMANDLA, M; MADISON, E L; SEMPLE, J E; SIEV,  
D V; VLASUK, G P  
PATENT ASSIGNEE(S): (CORV-N) CORVAS INT INC  
COUNTRY COUNT: 100  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
-----					
WO 2002095007	A2	20021128	(200321)*	EN	579
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ					
NL OA PT SD SE SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK					
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR					
KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT					
RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM					
ZW					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----			
WO 2002095007	A2	WO 2002-US16819	20020523

PRIORITY APPLN. INFO: US 2001-293267P 20010523  
AN 2003-221280 [21] WPIDS  
AB WO 200295007 A UPAB: 20030328

NOVELTY - A conjugate (I) comprising a therapeutic agent and a peptidic or nucleic acid substrate linked to it optionally by a peptidic linker, where the peptidic substrate is proteolytically cleaved by a cell surface protease or a soluble, released or shed form of it, to liberate the therapeutic agent, and (I) is not substantially cleaved by plasmin or prostate specific antigen (PSA), is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a **pharmaceutical composition** (II) comprising (I) or its derivative, in a carrier;
- (2) an article of manufacture (III) comprising (I) or its derivative, contained within packaging material, which is used for **treatment**, prevention or amelioration of one or more symptoms associated with cell-surface protease-associated diseases or disorders, and a label that indicates that (I) or its derivative is used for **treatment**, prevention or amelioration of the symptoms associated with cell-surface protease-associated diseases or disorders;
- (3) preparation of (I); and
- (4) identifying proteases to target conjugates for **treatment** of diseases by selecting a disease, identifying a cell involved in the disease process or a cell in the vicinity of the cell involved in the disease process, and identifying a cell surface protease on the cell.

ACTIVITY - Immunosuppressive; Antiinflammatory; Cytostatic; Vulnerary; Cardiant; Dermatological; Antirheumatic; Antiarthritic; Antipsoriatic; Antidiabetic; Ophthalmological; Anti-tumor.

Experimental protocols are given, but results not given.

MECHANISM OF ACTION - None given.

USE - (I) is useful for **treating** a cell-surface protease-associated disease such as autoimmune, inflammatory, infectious, endocrine or proliferative disease in a mammal, preferably human. The disease is selected from cancer, ocular diseases, cardiovascular diseases, chronic inflammatory diseases, wounds, circulatory disorders, dermatological disorders, rheumatoid arthritis, psoriasis, diabetic retinopathies, recurrence of pterygii, scarring from excimer laser surgery, scarring from glaucoma filtering surgery, macular degeneration anterior eye, crest syndromes, solid neoplasms, vascular tumors, melanoma, Kaposi's sarcoma, or lung, colon, pancreatic, esophageal, breast, ovarian or prostate cancer (claimed). (I) is useful for targeted delivery of therapeutic agents.

Dwg.0/5

L68 ANSWER 57 OF 89 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
DUPLICATE 5

ACCESSION NUMBER: 2002:115060 BIOSIS  
DOCUMENT NUMBER: PREV200200115060  
TITLE: Antiviral ricin-like proteins.  
AUTHOR(S): Borgford, Thor (1)  
CORPORATE SOURCE: (1) Burnaby Canada  
ASSIGNEE: Twinstrand Therapeutics Inc., Vancouver, Canada  
PATENT INFORMATION: US 6333303 December 25, 2001  
SOURCE: Official Gazette of the United States Patent and Trademark  
Office Patents, (Dec. 25, 2001) Vol. 1253, No. 4, pp. No  
Pagination. <http://www.uspto.gov/web/menu/patdata.html>.  
e-file.  
ISSN: 0098-1133.  
DOCUMENT TYPE: Patent  
LANGUAGE: English

AB The present invention provides a protein having an A chain of a **ricin-like** toxin, a B chain of a **ricin-like** toxin and a heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a retroviral **protease**. The invention also relates to a nucleic acid molecule encoding the protein and to expression vectors incorporating the nucleic acid molecule. Also provided is a method of inhibiting or destroying mammalian cells infected with a retrovirus utilizing the proteins of the

invention and pharmaceutical compositions for  
treating HIV infection.

L68 ANSWER 58 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2001:233125 USPATFULL  
TITLE: ADENOVIRUS VECTORS CONTAINING CELL STATUS-SPECIFIC  
RESPONSE ELEMENTS AND METHODS OF USE THEREOF  
INVENTOR(S): YU, DE CHAO, FOSTER CITY, CA, United States  
HENDERSON, DANIEL R., PALO ALTO, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001053352	A1	20011220
APPLICATION INFO.:	US 1999-392822	A1	19990909 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-99791P	19980910 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gladys H. Monroy, MORRISON & FOERSTER LLP, 755 PAGE MILL ROAD, PALO ALTO, CA, 94304-1018	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	27 Drawing Page(s)	
LINE COUNT:	1768	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A "cell status" is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using the vectors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 59 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2001:102373 USPATFULL  
TITLE: Adenovirus vectors specific for cells expressing  
alpha-fetoprotein and methods of use thereof  
INVENTOR(S): Little, Andrew S., Los Altos, CA, United States  
Henderson, Daniel R., Palo Alto, CA, United States  
Schuur, Eric R., Palo Alto, CA, United States  
Lamparski, Henry, San Mateo, CA, United States  
PATENT ASSIGNEE(S): Calydon, Inc., Sunnyvale, CA, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6254862	B1	20010703
APPLICATION INFO.:	US 1998-33428		19980302 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-39597P	19970303 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Guzo, David	
LEGAL REPRESENTATIVE:	Morrison & Foerster LLP	
NUMBER OF CLAIMS:	63	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	25 Drawing Figure(s); 17 Drawing Page(s)	
LINE COUNT:	2712	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Adenovirus vectors replication specific for cells expressing .alpha.-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor samples for the presence of AFP-producing cells as well as to kill selectively malignant cells producing AFP.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 60 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2001:82308 USPATFULL  
TITLE: Method for **treating** brain cancer with a conditionally lethal gene  
INVENTOR(S): Barber, Jack R., San Diego, CA, United States  
Gruber, Harry E., San Diego, CA, United States  
Jolly, Douglas J., Leucadia, CA, United States  
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6241982	B1	20010605
APPLICATION INFO.:	US 1995-468646		19950606 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-155944, filed on 18 Nov 1993, now abandoned Continuation-in-part of Ser. No. US 1993-139994, filed on 20 Oct 1993, now abandoned Continuation of Ser. No. US 1992-965084, filed on 22 Oct 1992, now abandoned Continuation of Ser. No. US 1990-586603, filed on 21 Sep 1990, now abandoned Continuation-in-part of Ser. No. US 1990-565606, filed on 10 Aug 1990, now abandoned Continuation-in-part of Ser. No. US 1989-395932, filed on 18 Aug 1989, now abandoned Continuation-in-part of Ser. No. US 1988-170515, filed on 21 Mar 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schwartzman, Robert A.		
LEGAL REPRESENTATIVE:	Pochopien, Donald, Dollard, Anne, Blackburn, Robert		
NUMBER OF CLAIMS:	34		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	30 Drawing Figure(s); 25 Drawing Page(s)		
LINE COUNT:	2796		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides recombinant viral vectors carrying a vector construct which directs the expression of a gene product (e.g., HSVTK) that activates a compound with little or no cytotoxicity into a toxic product. Also provided are methods of destroying or inhibiting pathogenic agents in a warm blooded animal, comprising the step of administering to the animal a viral vector such as that described above, in order to inhibit or destroy the pathogenic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 61 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2001:59379 USPATFULL  
TITLE: Anti-pathogen system and methods of use thereof  
INVENTOR(S): Dowdy, Steven F., Clayton, MO, United States  
PATENT ASSIGNEE(S): Washington University, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6221355	B1	20010424

APPLICATION INFO.: US 1998-208966 19981210 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-82402P	19980420 (60)
	US 1997-69012P	19971210 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Park, Hankyel T.	
LEGAL REPRESENTATIVE:	Buchanan, Robert L., Schray, Kerri Pollard, Corless, Peter F.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	26 Drawing Figure(s); 16 Drawing Page(s)	
LINE COUNT:	3168	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 62 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2001:40010 USPATFULL  
TITLE: Modification of clostridial toxins for use as transport proteins  
INVENTOR(S): Dolly, James Oliver, Cheam, United Kingdom  
Aoki, Kei Roger, Laguna Hills, CA, United States  
Wheeler, Larry Allen, Irvine, CA, United States  
Garst, Michael Elwood, Newport Beach, CA, United States  
PATENT ASSIGNEE(S): Allergan Sales, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6203794	B1	20010320
	WO 9532738		19951207
APPLICATION INFO.:	US 1997-750101		19970501 (8)
	WO 1995-GB1253		19950531
			19970501 PCT 371 date
			19970501 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-10870	19940531
	GB 1994-10871	19940531
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Minnifield, Nita	
LEGAL REPRESENTATIVE:	Fisher, Carlos A., Baran, Robert J., Voet, Martin A.	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 9 Drawing Page(s)	
LINE COUNT:	2053	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A chemical conjugate for **treating** a nerve cell related disorder is provided. The conjugate includes an active or inactive Clostridial toxin having specificity for a target nerve cell. The toxin is conjugated to a drug or other bioactive molecule without affecting the toxin's ability to enter the target nerve cell.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 63 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2001:32791 USPATFULL  
TITLE: Adenovirus vectors specific for cells expressing  
androgen receptor and methods of use thereof  
INVENTOR(S): Henderson, Daniel R., Palo Alto, CA, United States  
Schuur, Eric R., Palo Alto, CA, United States  
Yu, De-Chao, Foster City, CA, United States  
PATENT ASSIGNEE(S): Calydon, Inc., Sunnyvale, CA, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6197293	B1	20010306
APPLICATION INFO.:	US 1998-33333		19980302 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-39762P	19970303 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Guzo, David	
LEGAL REPRESENTATIVE:	Morrison & Forester LLP	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	3396	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Replication-competent adenovirus vectors specific for cells which allows a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells. An adenovirus of the present invention can further comprise a heterologous gene such as a reporter under transcriptional control of a PB-TRE. The adenovirus vectors can be used to detect and monitor samples for the presence of prostate cells as well as to selectively kill malignant cells producing prostate-specific gene products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 64 OF 89 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN  
ACCESSION NUMBER: 2001-300164 [31] WPIDS  
DOC. NO. CPI: C2001-092131  
TITLE: New proteins comprising A and B chains of **ricin**  
-like toxin linked by a novel linker sequence that is  
specifically cleaved and activated by **protease**  
specific to cancer is useful for **treating**  
inflammation and cancer.  
DERWENT CLASS: B04 D16  
INVENTOR(S): BORGFOR, T; BRAUN, C; PURAC, A  
PATENT ASSIGNEE(S): (TWIN-N) TWINSTRAND THERAPEUTICS INC  
COUNTRY COUNT: 94  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
-----					

WO 2001025267 A2 20010412 (200131)\* EN 146  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
 NL OA PT SD SE SL SZ TZ UG ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM  
 DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC  
 LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE  
 SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
 AU 2000076368 A 20010510 (200143)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2001025267	A2	WO 2000-CA1162	20001004
AU 2000076368	A	AU 2000-76368	20001004

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2000076368	Based on	WO 2001025267

PRIORITY APPLN. INFO: US 2000-197409P 20000414; US 1999-157807P  
 19991004

AN 2001-300164 [31] WPIDS

AB WO 200125267 A UPAB: 20010607

NOVELTY - A recombinant protein (I) comprising an A chain of a **ricin**-like toxin, a B chain of a **ricin**-like toxin and a heterologous linker (L) amino acid sequence that links the A and B chains and comprising a cleavage recognition site for a specific **protease**, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a purified and isolated nucleic acid molecule (II) comprising:
  - (a) a nucleotide sequence encoding an A chain of a ricin-like toxin;
  - (b) a nucleotide sequence encoding a B chain of a ricin-like toxin;
 and
  - (c) a nucleotide sequence encoding (L);
  - (2) a plasmid incorporating (II);
  - (3) a baculovirus transfer vector incorporating (II);
  - (4) preparing a pharmaceutical for **treating** a cell having a specific protease, by preparing and introducing (II) into a host cell, expressing (II) in the host cell to obtain (I), and suspending the protein in a pharmaceutically acceptable carrier, diluent or excipient;
  - (5) a **pharmaceutical composition** (PC) for **treating** cancer and inflammation comprising (I);
  - (6) a **pharmaceutical composition** for **treating** a cell having a specific protease, comprising (I) or (II);
  - (7) a purified and isolated nucleic acid molecule comprising a nucleic acid sequence of pAP301, pAP302, pAP303, pAP304, pAP305, pAP308, pAP309, pAP313, pAP314, pAP315, pAP316, pAP318, pAP320, pAP321, pAP322, pAP323, pAP324 or pAP325, sequences being fully defined in the specification;
  - (8) inhibiting or destroying cells having a specific protease comprising:
    - (a) preparing (II);
    - (b) introducing (II) into a host cell and expressing (II) to obtain (I);
    - (c) suspending (I) in a pharmaceutically acceptable carrier, diluent or excipient; and
    - (d) contacting the cells with the recombinant protein; and
    - (9) a linker protein comprising an amino acid sequence of PAP301, PAP302, PAP303, PAP304, PAP305, PAP308, PAP309, PAP313, PAP314, PAP315, PAP316, PAP318, PAP320, PAP321, PAP322, PAP323, PAP324 or PAP325, the

sequences being fully defined in the specification.

ACTIVITY - Cytostatic; antiinflammatory; antirheumatic; antiarthritic; antiarteriosclerotic; neuroprotective.

BDF-1 mice, grouped according to body weight, were inoculated with 1 multiply 10<sup>6</sup> cells implanted subcutaneously in the flank. P388 murine leukemia cells from the ATCC tumor repository were maintained as an ascitic fluid in the BDF-1 mouse which were passaged to new mice weekly. The cells used for experiment were used within passage 3-20. The cells were rinsed with Hanks Balanced Salt Solution, counted on a hemocytometer and diluted with HBSS to a concentration of 20 multiply 10<sup>6</sup> cells/ml. PAP034 was injected intravenously on days 3, 6 and 9 after tumor injection. The results showed a significant delay in tumor growth in the murine tumor model.

MECHANISM OF ACTION - None given.

USE - (II) is useful for inhibiting or destroying cells having a specific protease e.g., cancer cell found in T- and B-cell lymphoproliferative diseases, ovarian cancer, pancreatic cancer, head and neck cancer, squamous cell carcinoma, gastrointestinal cancer, breast cancer, prostate cancer or non-small cell lung cancer, or cells found in rheumatoid arthritis, atherosclerosis, Crohn's disease or central nervous system disease, by introducing (II) into a host cell and expressing (II) in the host cell to obtain (I), and contacting the diseased cells with (I). (I) is also useful for inhibiting or destroying cells having a specific protease. PC is useful for **treating** cancer and inflammation (claimed).

ADVANTAGE - (I) has the specificity for cells that contain a specific protease, including those of inflammatory disorders and cancer cells, without the need for a cell binding component.

Dwg.0/22

L68 ANSWER 65 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2000:142359 USPATFULL  
TITLE: Prostate specific enhancer polynucleotides and methods of use thereof  
INVENTOR(S): Henderson, Daniel R., Palo Alto, CA, United States  
PATENT ASSIGNEE(S): Calydon, Inc., Sunnyvale, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6136792		20001024
APPLICATION INFO.:	US 1997-891581		19970711 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-380916, filed on 30 Jan 1995, now patented, Pat. No. US 5648478 which is a continuation-in-part of Ser. No. US 1994-182247, filed on 13 Jan 1994, now patented, Pat. No. US 5830686		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Crouch, Deborah		
LEGAL REPRESENTATIVE:	Morrison & Foerster, LLP		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Figure(s); 21 Drawing Page(s)		
LINE COUNT:	1773		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a human prostate-specific transcriptional regulatory sequence, polynucleotide comprising such regulatory regions, toxin gene constructs wherein a toxin gene is expressed under the transcriptional control of a human prostate-specific transcriptional regulatory sequence, and methods for **treating** prostate disease using such toxin gene constructs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 66 OF 89 USPATFULL on STN



ACCESSION NUMBER: 2000:138119 USPATFULL  
 TITLE: Replication defective viral vectors for infecting human cells  
 INVENTOR(S): Gruber, Harry E., San Diego, CA, United States  
 Jolly, Douglas J., La Jolla, CA, United States  
 Respass, James G., San Diego, CA, United States  
 Laikind, Paul K., San Diego, CA, United States  
 PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6133029		20001017
APPLICATION INFO.:	US 1995-479672		19950606 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-344743, filed on 23 Nov 1994, now abandoned which is a continuation of Ser. No. US 1993-139994, filed on 20 Oct 1993, now abandoned which is a continuation of Ser. No. US 1992-965084, filed on 22 Oct 1992, now abandoned which is a continuation of Ser. No. US 1990-586603, filed on 21 Sep 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-565606, filed on 10 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-395932, filed on 18 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-170515, filed on 21 Mar 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schwartzman, Robert A.		
LEGAL REPRESENTATIVE:	Pochopien, Donald J., Blackburn, Robert P.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	48 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	4508		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and **pharmaceutical compositions** containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 67 OF 89 USPATFULL on STN  
 ACCESSION NUMBER: 2000:54082 USPATFULL  
 TITLE: Tissue-specific enhancer active in prostate  
 INVENTOR(S): Henderson, Daniel R., Palo Alto, CA, United States  
 PATENT ASSIGNEE(S): Calydon, Inc., Sunnyvale, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6057299		20000502
APPLICATION INFO.:	US 1996-721690		19960927 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-380916, filed on 30 Jan 1995, now patented, Pat. No. US 5648478 which is a continuation-in-part of Ser. No. US 1994-182247, filed on 13 Jan 1994, now patented, Pat. No. US 5830686		

And a continuation-in-part of Ser. No. US 1996-669753,  
filed on 26 Jun 1996, now patented, Pat. No. US 5871726  
which is a continuation-in-part of Ser. No. US  
1995-495034, filed on 27 Jun 1995, now patented, Pat.  
No. US 5698443

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Campell, Bruce R.  
ASSISTANT EXAMINER: Nguyen, Dave Trong  
LEGAL REPRESENTATIVE: Morrison & Foerster, LLP  
NUMBER OF CLAIMS: 34  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 24 Drawing Page(s)  
LINE COUNT: 2614

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a human prostate-specific transcriptional  
regulatory sequence, polynucleotide comprising such regulatory regions,  
toxin gene constructs wherein a toxin gene is expressed under the  
transcriptional control of a human prostate-specific transcriptional  
regulatory sequence, and methods for **treating** prostate disease  
using such toxin gene constructs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 68 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2000:7195 USPATFULL  
TITLE: Method for stimulating an immune response utilizing  
recombinant alphavirus particles  
INVENTOR(S): Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United  
States  
Polo, John M., San Diego, CA, United States  
Chang, Steven M.W., San Diego, CA, United States  
Jolly, Douglas J., Leucadia, CA, United States  
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6015694		20000118
APPLICATION INFO.:	US 1997-931869		19970916 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 18 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned		

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Brusca, John S.  
LEGAL REPRESENTATIVE: McMasters, David D., Blackburn, Robert P.  
NUMBER OF CLAIMS: 11  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 30 Drawing Page(s)  
LINE COUNT: 10431

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for utilizing  
recombinant alphavirus vectors. Also disclosed are compositions and  
methods for making and utilizing eukaryotic layered vector initiation  
systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 69 OF 89 USPATFULL on STN

ACCESSION NUMBER: 2000:7187 USPATFULL  
TITLE: Eukaryotic layered vector initiation systems  
INVENTOR(S): Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United States  
Polo, John M., San Diego, CA, United States  
Jolly, Douglas J., Leucadia, CA, United States  
Driver, David A., San Diego, CA, United States  
PATENT ASSIGNEE(S): Chiron Viagene, Inc., Emeryville, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6015686		20000118
APPLICATION INFO.:	US 1995-404796		19950315 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ketter, James		
ASSISTANT EXAMINER:	Brusca, John S.		
LEGAL REPRESENTATIVE:	Seed & Berry, Kruse, Norman J., Blackburn, Robert P.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	37 Drawing Figure(s); 30 Drawing Page(s)		
LINE COUNT:	10466		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 70 OF 89 USPATFULL on STN

ACCESSION NUMBER: 1999:159476 USPATFULL  
TITLE: Method for **treating** a metastatic carcinoma using a conditionally lethal gene  
INVENTOR(S): Barber, Jack R., San Diego, CA, United States  
Gruber, Harry E., San Diego, CA, United States  
Jolly, Douglas J., Leucadia, CA, United States  
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5997859		19991207
APPLICATION INFO.:	US 1995-467034		19950606 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-155944, filed on 18 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-139994, filed on 20 Oct 1993, now abandoned which is a continuation of Ser. No. US 1992-965084, filed on 22 Oct 1992, now abandoned which is a continuation of Ser. No. US 1990-586603, filed on 21 Sep 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-565606, filed on 10 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-395932, filed on 18 Aug 1989, now abandoned which is a		

continuation-in-part of Ser. No. US 1988-170515, filed  
on 21 Mar 1988, now abandoned

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Elliott, George C.  
ASSISTANT EXAMINER: Schwartzman, Robert  
LEGAL REPRESENTATIVE: Pochopien, Donald J., Blackburn, Robert P.  
NUMBER OF CLAIMS: 19  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 30 Drawing Figure(s); 25 Drawing Page(s)  
LINE COUNT: 2772  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides recombinant viral vectors carrying a  
vector construct which directs the expression of a gene product (e.g.,  
HSVTK) that activates a compound with little or no cytotoxicity into a  
toxic product. Also provided are methods of destroying or inhibiting  
pathogenic agents in a warm blooded animal, comprising the step of  
administering to the animal a viral vector such as that described above,  
in order to inhibit or destroy the pathogenic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 71 OF 89 USPATFULL on STN  
ACCESSION NUMBER: 1999:96482 USPATFULL  
TITLE: Recombinant antibodies specific for a growth factor  
receptor  
INVENTOR(S): Wels, Winfried Stephan, Basel, Switzerland  
Hynes, Nancy E., Basel, Switzerland  
Harwerth, Ina-Maria, Grenzach-Wyhlen, Germany, Federal  
Republic of  
Groner, Bernd, Basel, Switzerland  
Hardman, Norman, Riehen, Switzerland  
Zwickl, Markus, Basel, Switzerland  
PATENT ASSIGNEE(S): Novartis Corp., Basel, Switzerland (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5939531		19990817
APPLICATION INFO.:	US 1995-465473		19950605 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-235838, filed on 29 Apr 1994, now patented, Pat. No. US 5571894 which is a continuation of Ser. No. US 1992-828832, filed on 31 Jan 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-731190, filed on 15 Jul 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Feisee, Lila		
ASSISTANT EXAMINER:	Kaufman, Claire M.		
LEGAL REPRESENTATIVE:	Pfeiffer, Hesna J.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3446		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns recombinant antibodies directed to the  
extracellular domain of the human growth factor receptor c-erbB-2  
comprising a light chain variable domain and a heavy chain variable  
domain of a monoclonal antibody, monoclonal antibodies directed to  
c-erbB-2 themselves, a method of manufacture of said recombinant  
antibodies and said monoclonal antibodies, hybridoma cells secreting  
said monoclonal antibodies, a method of manufacture of said hybridoma  
cells, DNA coding for the heavy chain variable domain, for the light  
chain variable domain and for the recombinant antibody, a method of  
manufacture of said DNA, hybrid vectors suitable for expression of said

DNA, host cells transformed with said DNA, and the use of said recombinant antibodies and said monoclonal antibodies in the diagnosis and **treatment** of tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 72 OF 89 USPATFULL on STN

ACCESSION NUMBER: 1999:39929 USPATFULL  
TITLE: Recombinant retroviruses  
INVENTOR(S): Guber, Harry E., 13083 Maritime Pl., San Diego, CA, United States 92130  
Jolly, Douglas J., 3050 H Via Alicante Dr., La Jolla, CA, United States 92037  
Respass, James G., 4966 Lamont St., San Diego, CA, United States 92109  
Laikind, Paul K., 12433 Caminito Mira Del Mar, San Diego, CA, United States 92130

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5888502		19990330
APPLICATION INFO.:	US 1995-463122		19950605 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-136739, filed on 12 Oct 1993, now patented, Pat. No. US 5716826 which is a continuation of Ser. No. US 1989-395932, filed on 18 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-170515, filed on 21 Mar 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Schwartzman, Robert		
LEGAL REPRESENTATIVE:	Kruse, Norman J., Pochopien, Donald J., Blackburn, Robert P.		
NUMBER OF CLAIMS:	72		
EXEMPLARY CLAIM:	19		
NUMBER OF DRAWINGS:	31 Drawing Figure(s); 27 Drawing Page(s)		
LINE COUNT:	3337		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and **pharmaceutical compositions** containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 73 OF 89 USPATFULL on STN

ACCESSION NUMBER: 1999:1521 USPATFULL  
TITLE: Method for making reflection defective retroviral vectors for infecting human cells  
INVENTOR(S): Gruber, Harry E., San Diego, CA, United States  
Jolly, Douglas J., La Jolla, CA, United States  
Respass, James G., San Diego, CA, United States  
Laikind, Paul K., San Diego, CA, United States  
Barber, Jack R., San Diego, CA, United States  
St. Louis, Daniel C., Rockville, MD, United States  
Chada, Sunil D., Vista, CA, United States

PATENT ASSIGNEE(S): Chang, Stephen M. W., San Diego, CA, United States  
Warner, John F., San Diego, CA, United States  
Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5856185		19990105
APPLICATION INFO.:	US 1995-472109		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-344743, filed on 23 Nov 1994, now abandoned which is a continuation of Ser. No. US 1993-139994, filed on 20 Oct 1993, now abandoned which is a continuation of Ser. No. US 1992-965084, filed on 22 Oct 1992, now abandoned which is a continuation of Ser. No. US 1990-586603, filed on 21 Sep 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-565606, filed on 10 Aug 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-395932, filed on 18 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-170515, filed on 21 Mar 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Schwartzman, Robert		
LEGAL REPRESENTATIVE:	Pochopien, Donald, Kruse, Norman J., Blackburn, Robert P.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	54 Drawing Figure(s); 44 Drawing Page(s)		
LINE COUNT:	4588		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and **pharmaceutical compositions** containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 74 OF 89 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN  
ACCESSION NUMBER: 2000-105833 [09] WPIDS  
DOC. NO. CPI: C2000-031780  
TITLE: Novel recombinant immunotoxin directed against the HIV- 1 gp120 coat protein useful for **treating** HIV-1 infections.  
DERWENT CLASS: B04 D16  
INVENTOR(S): BARBAS, C F; BERA, T K; BERGER, E A; KENNEDY, P E; PASTAN, I H  
PATENT ASSIGNEE(S): (SCRI) SCRIPPS RES INST; (USSH) US DEPT HEALTH & HUMAN SERVICES  
COUNTRY COUNT: 87  
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9964073	A2	19991216	(200009)*	EN	50
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL					

OA PT SD SE SL SZ UG ZW  
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB  
GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU  
LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR  
TT UA UG US UZ VN YU ZA ZW  
AU 9946772 A 19991230 (200022)  
EP 1085908 A2 20010328 (200118) EN  
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
AU 763118 B 20030710 (200355)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9964073	A2	WO 1999-US12909	19990608
AU 9946772	A	AU 1999-46772	19990608
EP 1085908	A2	EP 1999-930180	19990608
		WO 1999-US12909	19990608
AU 763118	B	AU 1999-46772	19990608

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9946772	A Based on	WO 9964073
EP 1085908	A2 Based on	WO 9964073
AU 763118	B Previous Publ. Based on	AU 9946772 WO 9964073

PRIORITY APPLN. INFO: US 1998-88860P 19980611

AN 2000-105833 [09] WPIDS

AB WO 9964073 A UPAB: 20000218

NOVELTY - A novel chimeric cytotoxin is specifically capable of targeting and killing cells displaying a HIV-1 gp120 coat protein. The immunotoxin comprises a 3B3 antibody attached to a cytotoxic moiety. As the gp120 protein is displayed on cells that are not dividing and in which HIV is not rapidly propagating, the chimeric cytotoxin kills cells that act as quiescent reservoirs of HIV.

DETAILED DESCRIPTION - A novel immunotoxin (I) comprises a cytotoxin attached to an anti-gp120 antibody having the binding specificity of 3B3 and a minimum binding affinity of 3B3, where the immunotoxin specifically binds to and kills mammalian cells infected with HIV-1.

INDEPENDENT CLAIMS are also included for the following:

- (1) a nucleic acid that encodes a single chain fusion protein, comprising:
  - (a) a nucleic acid sequence encoding a single-chain antibody having the binding specificity of 3B3; and
  - (b) a nucleic acid sequence encoding a modified Pseudomonas exotoxin;
- (2) a single chain Fv antibody having the binding specificity of 3B3;
- (3) a nucleic acid that encoded the antibody of (2);
- (4) killing a cell displaying a gp120 protein or fragment, comprising contacting the cell with an immunotoxin comprising a modified Pseudomonas exotoxin attached to an anti-gp120 antibody having the binding specificity of 3B3;
- (5) killing or inhibiting the growth of cells displaying a gp120 protein or fragment, comprising administering to an organism containing the cells a **pharmaceutical composition** comprising an immunotoxin comprising a modified Pseudomonas exotoxin attached to an anti-gp120 antibody having the binding specificity of 3B3, and
- (6) a kit for killing cells that display a gp120 protein or fragment, comprising an immunotoxin comprising a cytotoxin attached to an anti-gp120 antibody having the binding specificity of 3B3 and a minimum binding affinity of 3B3.

ACTIVITY - Anti-HIV.

MECHANISM OF ACTION - None given.

USE - The chimeric immunotoxins of the invention are used to target and kill cells that display a Human immunodeficiency virus type 1 (HIV-1) gp120 coat protein. As the gp120 protein is displayed on cells that are not dividing and in which HIV is not rapidly propagating, the chimeric cytotoxin kills cells that act as quiescent reservoirs of HIV. By specifically attacking a killing cells that act as HIV reservoirs, the immunotoxins augment the activities of reverse transcriptase inhibitors and protease inhibitors in purging the organism of HIV. The immunotoxins also have may other uses apart form HIV **treatment**, e.g. the immunotoxins can be used ex vivo to reduce and/or eliminate the HIV viral load of cells, tissues or organs derived from HIV-infected organisms. This will be of use in reducing or eliminating HIV-infected cells in culture, e.g. either where the cells are going to be propagated or prior to re-infusion back to the donor. The immunotoxins can also be used in establishing transformed cell lines derived from HIV-infected sources or in providing cells or tissues for transplant where there is no compatible donor other than an HIV-infected organism. The immunotoxins can also be used for detecting the presence or absence, and for quantifying the number of infected cells.

ADVANTAGE - The immunotoxin has a high affinity and a broad cross-reactivity with many laboratory and clinical isolates of HIV. Also, it is believed that the immunotoxin of the invention will be tolerated at significantly higher doses than a CD4-directed immunotoxin, and will also show significantly higher specific toxicity to cells displaying a gp120 protein than the CD4-directed immunotoxin.

Dwg.0/2

L68 ANSWER 75 OF 89 USPATFULL on STN

ACCESSION NUMBER: 1998:159468 USPATFULL

TITLE: Recombinant retroviruses

INVENTOR(S): Guber, Harry E., 13083 Maritime Pl., San Diego, CA, United States 92130  
Jolly, Douglas J., 3050H Via Alicante Dr., La Jolla, CA, United States 92037  
Respass, James G., 4966 Lamont St., San Diego, CA, United States 92109  
Laikind, Paul K., 12433 Caminito Mira Del Mar, San Diego, CA, United States 92130

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5851529		19981222
APPLICATION INFO.:	US 1995-477890		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-136739, filed on 12 Oct 1993 which is a continuation of Ser. No. US 1989-395932, filed on 18 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-170515, filed on 21 Mar 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Schwartzman, Robert		
LEGAL REPRESENTATIVE:	Kruse, Norman J. Seed & Berry, Blackburn, Robert P.		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	31 Drawing Figure(s); 27 Drawing Page(s)		
LINE COUNT:	3017		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell



receptor. In addition, eucaryotic cells infected with, and **pharmaceutical compositions** containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 76 OF 89 USPATFULL on STN

ACCESSION NUMBER: 1998:150739 USPATFULL  
TITLE: Alphavirus vector constructs  
INVENTOR(S): Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United States  
Polo, John M., San Diego, CA, United States  
Ibanez, Carlos E., San Diego, CA, United States  
Chang, Stephen M. W., San Diego, CA, United States  
Jolly, Douglas J., Leucadia, CA, United States  
Driver, David A., San Diego, CA, United States  
Belli, Barbara A., San Diego, CA, United States  
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843723		19981201
APPLICATION INFO.:	US 1996-739167		19961030 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-404796, filed on 20 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ketter, James		
ASSISTANT EXAMINER:	Brusca, John S.		
LEGAL REPRESENTATIVE:	McMasters, David D., Kruse, Norman J., Blackburn, Robert P.		
NUMBER OF CLAIMS:	47		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	37 Drawing Figure(s); 30 Drawing Page(s)		
LINE COUNT:	10318		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and method,, for utilizing recombinant alphavirus vectors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 77 OF 89 USPATFULL on STN

ACCESSION NUMBER: 1998:134840 USPATFULL  
TITLE: Tissue-specific enhancer active in prostate  
INVENTOR(S): Henderson, Daniel R., Palo Alto, CA, United States  
PATENT ASSIGNEE(S): Calydon, Menlo Park, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5830686		19981103
APPLICATION INFO.:	US 1994-182247		19940113 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Stone, Jacqueline M.		

ASSISTANT EXAMINER: Hogue, Jr., D. Curtis  
LEGAL REPRESENTATIVE: Rowland, Bertram I. Flehr, Hohbach, Test, Albritton & Herbert

NUMBER OF CLAIMS: 1  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)  
LINE COUNT: 1169

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a human prostate-specific transcriptional regulatory sequence, polynucleotides comprising such regulatory regions, toxin gene constructs wherein a toxin gene is expressed under the transcriptional control of a human prostate-specific transcriptional regulatory sequence, and methods for **treating** prostate disease using such toxin gene constructs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 78 OF 89 USPATFULL on STN

ACCESSION NUMBER: 1998:134622 USPATFULL  
TITLE: Method for destroying a diseased human cell  
INVENTOR(S): Gruber, Harry E., P.O. Box 675272, Rancho Santa Fe, CA, United States 92067  
Jolly, Douglas J., 277 Hillcrest Dr., Leucadia, CA, United States 92024  
Respass, James G., 4966 Lamont St., San Diego, CA, United States 92109  
Laikind, Paul K., 3370 Goldfinch St., San Diego, CA, United States 92103

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5830458		19981103
APPLICATION INFO.:	US 1995-487776		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-136739, filed on 12 Oct 1993, now patented, Pat. No. US 5716826 which is a continuation of Ser. No. US 1989-395932, filed on 18 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-170515, filed on 21 Mar 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George D.		
ASSISTANT EXAMINER:	Schwartzman, Robert		
LEGAL REPRESENTATIVE:	Kruse, Norman J., Pochopien, Donald J., Blackburn, Robert P.		
NUMBER OF CLAIMS:	38		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	31 Drawing Figure(s); 27 Drawing Page(s)		
LINE COUNT:	3199		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and **pharmaceutical compositions** containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 79 OF 89 USPATFULL on STN

ACCESSION NUMBER: 1998:119004 USPATFULL  
TITLE: Eukaryotic layered vector initiation systems  
INVENTOR(S): Dubensky, Jr., Thomas W., P.O. Box 675205, Rancho Sante Fe, CA, United States 92067  
Polo, John M., 1222 Reed Ave., Number 4, San Diego, CA, United States 92109  
Jolly, Douglas J., 277 Hillcrest Dr., Leucadia, CA, United States 92024  
Driver, David A., 5142 Biltmore St., San Diego, CA, United States 92117

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5814482		19980929
APPLICATION INFO.:	US 1996-739158		19961030 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 18 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed on 18 Feb 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-122791, filed on 15 Sep 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ketter, James		
ASSISTANT EXAMINER:	Brusca, John S.		
LEGAL REPRESENTATIVE:	Seed & Berry, Kruse, Norman J., Blackburn, Robert P.		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	37 Drawing Figure(s); 30 Drawing Page(s)		
LINE COUNT:	10431		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 80 OF 89 USPATFULL on STN

ACCESSION NUMBER: 1998:91872 USPATFULL  
TITLE: Alphavirus structural protein expression cassettes  
INVENTOR(S): Dubensky, Jr., Thomas W., Rancho Sante Fe, CA, United States  
Polo, John M., San Diego, CA, United States  
Ibanez, Carlos E., San Diego, CA, United States  
Chang, Stephen M. W., San Diego, CA, United States  
Jolly, Douglas J., Leucadia, CA, United States  
Driver, David A., San Diego, CA, United States  
PATENT ASSIGNEE(S): Chiron Corporation, Emeryville, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5789245		19980804
APPLICATION INFO.:	US 1996-741881		19961030 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-404796, filed on 15 Mar 1995 which is a continuation-in-part of Ser. No. US 1995-376184, filed on 20 Jan 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-348472, filed on 30 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-198450, filed		

on 18 Feb 1994, now abandoned which is a  
continuation-in-part of Ser. No. US 1993-122791, filed  
on 15 Sep 1993, now abandoned

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Ketter, James  
ASSISTANT EXAMINER: Brusca, John S.  
LEGAL REPRESENTATIVE: McMasters, David D., Kruse, Norman J., Blackburn,  
Robert P.

NUMBER OF CLAIMS: 29  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 35 Drawing Figure(s); 30 Drawing Page(s)  
LINE COUNT: 10270

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for utilizing  
recombinant alphavirus vectors. Also disclosed are compositions and  
methods for making and utilizing eukaryotic layered vector initiation  
systems.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 81 OF 89 USPATFULL on STN

ACCESSION NUMBER: 1998:75590 USPATFULL

TITLE: Quinazolines as inhibitors of endothelin converting  
enzyme

INVENTOR(S): Ahn, Kyunghye, Ann Arbor, MI, United States  
Cheng, Xue-Min, Ann Arbor, MI, United States  
Doherty, Annette Marian, Ann Arbor, MI, United States  
Elslager, Edward Faith, Ann Arbor, MI, United States  
Kornberg, Brian, Ann Arbor, MI, United States  
Lee, Chitase, Ann Arbor, MI, United States  
Leonard, Daniele, Ann Arbor, MI, United States  
Nikam, Sham, Ann Arbor, MI, United States  
Werbel, Leslie Morton, Ann Arbor, MI, United States  
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United  
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5773444		19980630
APPLICATION INFO.:	US 1997-837176		19970414 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-363104, filed on 22 Dec 1994, now patented, Pat. No. US 5658902		

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Criares, Theodore J.  
LEGAL REPRESENTATIVE: Tinney, Francis J.  
NUMBER OF CLAIMS: 5  
EXEMPLARY CLAIM: 1  
LINE COUNT: 1838

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel quinazoline inhibitors of endothelin converting enzyme are  
described, as well as methods for the preparation and  
**pharmaceutical compositions** of the same, which are  
useful in **treating** elevated levels of endothelin and in  
controlling hypertension, myocardial infarction and ischemia, metabolic,  
endocrinological, and neurological disorders, congestive heart failure,  
endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage,  
arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A  
induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel  
disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic  
disorders including Raynaud's disease and restenosis, cerebral ischemia  
and vasospasm, and diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 82 OF 89 USPATFULL on STN

ACCESSION NUMBER: 1998:57716 USPATFULL  
TITLE: Aptamers specific for biomolecules and methods of making  
INVENTOR(S): Griffin, Linda, Atherton, CA, United States  
Albrecht, Glenn, Redwood City, CA, United States  
Latham, John, Palo Alto, CA, United States  
Leung, Lawrence, Hillsborough, CA, United States  
Vermaas, Eric, Oakland, CA, United States  
Toole, John J., Burlingame, CA, United States  
PATENT ASSIGNEE(S): Gilead Sciences, Inc., Foster City, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5756291		19980526
APPLICATION INFO.:	US 1995-484192		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-934387, filed on 21 Aug 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Zitomer, Stephanie W.		
LEGAL REPRESENTATIVE:	Bosse, Mark L.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	8242		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for identifying oligomer sequences, optionally comprising modified base, which specifically bind target molecules such as serum proteins, kinins, eicosanoids and extracellular proteins is described. The method is used to generate aptamers that bind to serum Factor X, PDGF, FGF, ICAM, VCAM, E-selectin, thrombin, bradykinin, PGF2 and cell surface molecules. The technique involves complexation of the target molecule with a mixture of oligonucleotides containing random sequences and sequences which serve as primer for PCR under conditions wherein a complex is formed with the specifically binding sequences, but not with the other members of the oligonucleotide mixture. The complex is then separated from uncomplexed oligonucleotides and the complexed members of the oligonucleotide mixture are recovered from the separated complex using the polymerase chain reaction. The recovered oligonucleotides may be sequenced, and successive rounds of selection using complexation, separation, amplification and recovery can be employed. The oligonucleotides can be used for therapeutic and diagnostic purposes and for generating secondary aptamers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 83 OF 89 USPATFULL on STN

ACCESSION NUMBER: 1998:14678 USPATFULL  
TITLE: Recombinant retroviruses  
INVENTOR(S): Gruber, Harry E., Rancho Santa Fe, CA, United States  
Jolly, Douglas J., Leucadia, CA, United States  
Respass, James G., San Diego, CA, United States  
Laikind, Paul K., San Diego, CA, United States  
PATENT ASSIGNEE(S): Chiron Viagene, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5716826		19980210
APPLICATION INFO.:	US 1993-136739		19931012 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1989-395932, filed on 18 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-170515, filed on 21 Mar 1988, now		

abandoned  
DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Elliott, George G.  
ASSISTANT EXAMINER: Schwartzman, Robert  
LEGAL REPRESENTATIVE: Kruse, Norman J.Seed & Berry, Blackburn, Robert P.  
NUMBER OF CLAIMS: 8  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 31 Drawing Figure(s); 27 Drawing Page(s)  
LINE COUNT: 2895

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and **pharmaceutical compositions** containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 84 OF 89 USPATFULL on STN

ACCESSION NUMBER: 1998:14473 USPATFULL  
TITLE: Recombinant retroviruses  
INVENTOR(S): Guber, Harry E., San Diego, CA, United States  
Jolly, Douglas J., La Jolla, CA, United States  
Respass, James G., San Diego, CA, United States  
Laikind, Paul K., San Diego, CA, United States  
PATENT ASSIGNEE(S): Chiron Viagene, Inc., United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5716613		19980210
APPLICATION INFO.:	US 1995-474736		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-136739, filed on 12 Oct 1993 which is a continuation of Ser. No. US 1989-395932, filed on 18 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-170515, filed on 21 Mar 1988, now abandoned		

DOCUMENT TYPE: Utility  
FILE SEGMENT: Granted  
PRIMARY EXAMINER: Elliott, George G.  
ASSISTANT EXAMINER: Schwartzman, Robert  
LEGAL REPRESENTATIVE: Kruse, Norman J.Seed & Berry, Blackburn, Robert P.  
NUMBER OF CLAIMS: 7  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 31 Drawing Figure(s); 27 Drawing Page(s)  
LINE COUNT: 2889

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and **pharmaceutical compositions** containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for

producing transgenic packaging animals or insects are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 85 OF 89 USPATFULL on STN

ACCESSION NUMBER: 97:109741 USPATFULL  
TITLE: Recombinant retroviruses expressing a protein that  
converts a pro-drug into a cytotoxic agent  
INVENTOR(S): Guber, Harry E., 13083 Maritime Pl., San Diego, CA,  
United States 92130  
Jolly, Douglas J., 3050 Via Alicante Dr., La Jolla, CA,  
United States 92037  
Respass, James G., 4966 Lamont St., San Diego, CA,  
United States 92109  
Laikind, Paul K., 12433 Caminito Mira Del Mar, San  
Diego, CA, United States 92130

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5691177		19971125
APPLICATION INFO.:	US 1995-460996		19950605 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1993-136739, filed on 12 Oct 1993 which is a continuation of Ser. No. US 1989-395932, filed on 18 Aug 1989, now abandoned which is a continuation-in-part of Ser. No. US 1988-170515, filed on 21 Mar 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Elliott, George G.		
ASSISTANT EXAMINER:	Railey, II, Johnny F.		
LEGAL REPRESENTATIVE:	Kruse, Norman J., Pochopien, Donald J., Blackburn, Robert P.		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	31 Drawing Figure(s); 27 Drawing Page(s)		
LINE COUNT:	3039		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Recombinant retroviruses carrying a vector construct capable of  
preventing, inhibiting, stabilizing or reversing infectious, cancerous  
or auto-immune diseases are disclosed. More specifically, the  
recombinant retroviruses of the present invention are useful for (a)  
stimulating a specific immune response to an antigen or a pathogenic  
antigen; (b) inhibiting a function of a pathogenic agent, such as a  
virus; and (c) inhibiting the interaction of an agent with a host cell  
receptor. In addition, eucaryotic cells infected with, and  
**pharmaceutical compositions** containing such a  
recombinant retrovirus are disclosed. Various methods for producing  
recombinant retroviruses having unique characteristics, and methods for  
producing transgenic packaging animals or insects are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 86 OF 89 USPATFULL on STN

ACCESSION NUMBER: 97:99261 USPATFULL  
TITLE: Diphtheria toxin fragments, conjugates and methods of  
use to inhibit tumors and leukemia  
INVENTOR(S): Villemez, Clarence L., Laramie, WY, United States  
Myers, Dean A., Ithaca, NY, United States  
PATENT ASSIGNEE(S): University of Wyoming, Laramie, WY, United States (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5681810		19971028
APPLICATION INFO.:	US 1995-472908		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1991-799684, filed on 22 Nov 1991 which is a continuation of Ser. No. US 1990-488812, filed on 5 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1988-165213, filed on 8 Mar 1988, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1989-89504	19890306
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Marschel, Ardin H.	
LEGAL REPRESENTATIVE:	Scully, Scott, Murphy & Presser	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	1035	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a modified diphtheria toxin (DT) and method of preparing the same in which two carboxy-terminal truncated forms of DT are prepared by specific chemical proteolysis generating two new proteins HA51DT and HA48DT which can be chemically linked to a cell specific binding moiety to produce potent cytotoxins. This invention further relates to carboxy terminal peptides formed in accordance with said proteolysis generating three peptides HA11DT, HA7DT and HA3DT.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 87 OF 89 USPATFULL on STN

ACCESSION NUMBER: 97:73609 USPATFULL

TITLE: Quinazolines as inhibitors of endothelin converting enzyme

INVENTOR(S): Ahn, Kyunghye, Ann Arbor, MI, United States  
Cheng, Xue-Min, Ann Arbor, MI, United States  
Doherty, Annette Marian, Ann Arbor, MI, United States  
Elslager, Edward Faith, Ann Arbor, MI, United States  
Kornberg, Brian, Ann Arbor, MI, United States  
Lee, Chitase, Ann Arbor, MI, United States  
Leonard, Daniele, Ann Arbor, MI, United States  
Nikam, Sham, Ann Arbor, MI, United States  
Werbel, Leslie Morton, Ann Arbor, MI, United States  
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5658902		19970819
APPLICATION INFO.:	US 1994-363104		19941222 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Wong, King Lit		
LEGAL REPRESENTATIVE:	Tinney, Francis J.		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1896		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and **pharmaceutical compositions** of the same, which are useful in **treating** elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A



induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 88 OF 89 USPATFULL on STN

ACCESSION NUMBER: 97:61806 USPATFULL  
TITLE: Tissue-specific enhancer active in prostate  
INVENTOR(S): Henderson, Daniel R., 769 Garland Dr., Palo Alto, CA,  
United States 94303

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5648478		19970715
APPLICATION INFO.:	US 1995-380916		19950130 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-182247, filed on 13 Jan 1994		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Stone, Jacqueline M.		
ASSISTANT EXAMINER:	Hogue, Jr., D. Curtis		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	2		
NUMBER OF DRAWINGS:	19 Drawing Figure(s); 18 Drawing Page(s)		
LINE COUNT:	1499		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides a human prostate-specific transcriptional regulatory sequence, polynucleotide comprising such regulatory regions, toxin gene constructs wherein a toxin gene is expressed under the transcriptional control of a human prostate-specific transcriptional regulatory sequence, and methods for **treating** prostate disease using such toxin gene constructs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L68 ANSWER 89 OF 89 USPATFULL on STN

ACCESSION NUMBER: 96:101658 USPATFULL  
TITLE: Recombinant antibodies specific for a growth factor receptor  
INVENTOR(S): Wels, Winfried S., Basel, Switzerland  
Hynes, Nancy E., Basel, Switzerland  
Harweth, Ina-Maria, Grenzach-Wyhlen, Germany, Federal Republic of  
Groner, Bernd, Basel, Switzerland  
Hardman, Norman, Riehen, Switzerland  
Zwickl, Markus, Basel, Switzerland  
PATENT ASSIGNEE(S): Ciba-Geigy Corporation, Tarrytown, NY, United States  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5571894		19961105
APPLICATION INFO.:	US 1994-235838		19940429 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1992-828832, filed on 31 Jan 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-731190, filed on 15 Jul 1991, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1991-810079	19910205
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	

PRIMARY EXAMINER: Walsh, Stephen G.  
ASSISTANT EXAMINER: Ulm, John P.  
LEGAL REPRESENTATIVE: Elmer, James Scott  
NUMBER OF CLAIMS: 19  
EXEMPLARY CLAIM: 1  
LINE COUNT: 3057

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns recombinant antibodies directed to the extracellular domain of the human growth factor receptor c-erbB-2 comprising a light chain variable domain and a heavy chain variable domain of a monoclonal antibody, monoclonal antibodies directed to c-erbB-2 themselves, a method of manufacturing those recombinant and monoclonal antibodies, hybridoma cells secreting those monoclonal antibodies, a method of manufacturing those hybridoma cells, DNAs encoding the heavy and light chain variable domains and the recombinant antibody, a method of manufacturing that DNA, hybrid vectors suitable for the expression of that DNA, host cells transformed with that DNA, and processes of using those recombinant and monoclonal antibodies in the diagnosis and **treatment** of tumors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>